On this page
Quick Reference
Overview and Recommendations
Background
- •Type 1 diabetes mellitus (T1DM), absolute insulin deficiency from autoimmune beta-cell destruction, affects approximately 1.45 million people in the United States, with a global incidence rising 3-4% per year, a pace too rapid for genetic drift alone.
- •The disease follows a predictable staging paradigm: Stage 1 (≥2 islet autoantibodies, normoglycemia), Stage 2 (autoantibodies plus dysglycemia), and Stage 3 (symptomatic hyperglycemia). Progression from Stage 1 to clinical diabetes occurs in >70% of individuals over 5 years.
- •The autoimmune attack targets well-characterized beta-cell antigens: GAD65 (glutamic acid decarboxylase), IA-2 (insulinoma-associated protein 2), ZnT8 (zinc transporter 8), and insulin. CD8+ cytotoxic T-cells mediate destruction via perforin/granzyme and Fas-FasL pathways.
- •Genetic susceptibility is dominated by HLA class II haplotypes DR3-DQ2 and DR4-DQ8 (OR >20 for heterozygotes), with additional risk from non-HLA loci including PTPN22, INS, CTLA4, and IL2RA. Environmental triggers, most consistently enteroviral infection, initiate or accelerate autoimmunity in genetically predisposed individuals.
Evaluation
- •Suspect T1DM in any patient with polyuria, polydipsia, unintentional weight loss (5-10% over weeks), fatigue, blurred vision, or new-onset nocturnal enuresis in children.
- •Ask about the duration of symptoms, classic T1DM progresses over 2-6 weeks in children and adolescents; adults may have a more insidious course over months.
- •Ask about family history of T1DM (RR 15 for first-degree relatives), other autoimmune diseases (thyroid, celiac, Addison's), and recent viral illness.
- •Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), Kussmaul respirations, acetone breath, and altered mental status indicating DKA.
- •Order STAT fingerstick blood glucose and urine or serum ketones (beta-hydroxybutyrate) in any symptomatic patient.
- •Confirm diabetes with fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%.
- •Assess for DKA using the triad: glucose >250 mg/dL, venous pH <7.3, serum bicarbonate <15 mEq/L, and positive ketones.
- •Measure C-peptide (fasting or stimulated) to distinguish T1DM from type 2 diabetes: fasting C-peptide <0.2 nmol/L (<0.6 ng/mL) confirms absolute insulin deficiency.
- •Order islet autoantibody panel (GADA, IA-2A, ZnT8A), ≥1 positive confirms autoimmune etiology; panel sensitivity is 85-90% at diagnosis.
- •If autoantibodies are negative, consider genetic testing for monogenic diabetes (WFS1, INS, GCK, HNF1A, HNF4A), especially in young children or those with family history.
- •Screen for associated autoimmune diseases at diagnosis: TSH and TPO antibodies (autoimmune thyroid disease in 15-30% of T1DM), tissue transglutaminase IgA (tTG-IgA) for celiac disease.
- •In a patient with DKA, assess severity by venous pH (mild pH 7.25-7.30, moderate pH 7.00-7.24, severe pH <7.00) and triage to appropriate level of care.
- •Use an algorithm for antibody-negative cases: if C-peptide low, consider idiopathic T1DM or monogenic diabetes; if C-peptide normal/high, consider type 2 diabetes or MODY.
Management
- •Initiate insulin therapy immediately once T1DM is confirmed. Start basal-bolus regimen at total daily dose (TDD) of 0.5-1.0 U/kg/day.
- •Administer 50% of TDD as basal insulin, insulin degludec (0.2-0.4 U/kg once daily), glargine U100 (0.2-0.4 U/kg once daily), or glargine U300 (0.3-0.5 U/kg once daily). Degludec reduces nocturnal hypoglycemia vs glargine (rate ratio 0.75, 95% CI 0.59-0.96).
- •Administer 50% of TDD as prandial rapid-acting analogue (lispro, aspart, glulisine) at 0.05-0.15 U/kg per meal, adjusted for carbohydrate content and premeal glucose.
- •For DKA: fluid resuscitation with 0.9% normal saline 15-20 mL/kg over first hour (1 L in adults), then 250-500 mL/h. Replace half the deficit over 8 hours.
- •For DKA: after fluids, give regular insulin 0.1 U/kg IV bolus, then 0.1 U/kg/h continuous IV infusion. Do not start insulin if K+ <3.3 mEq/L, replete potassium first.
- •When blood glucose falls to 250 mg/dL, add 5% dextrose to IV fluids and reduce insulin to 0.05-0.1 U/kg/h to maintain glucose 150-200 mg/dL until acidosis resolves.
- •Replace potassium when serum K+ <5.3 mEq/L: add 20-30 mEq potassium chloride or phosphate per liter IV fluid, target K+ 4-5 mEq/L. Monitor every 2 hours.
- •Reserve bicarbonate for pH <6.9: give 50-100 mEq NaHCO₃ in 200 mL sterile water over 30-60 minutes with ECG monitoring. Do not use routinely.
- •Transition from IV to subcutaneous insulin only after DKA resolves (anion gap <12 mEq/L, pH >7.3). Overlap IV and SC insulin by 1-2 hours.
- •Titrate all patients to HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults; target <7.5% for children and adolescents to balance hypoglycemia risk.
- •Prescribe continuous glucose monitoring (CGM) for all patients with T1DM, reduces severe hypoglycemia by 40-50% and improves HbA1c by 0.3-0.5% in adults ≥25 years.
- •Advanced hybrid closed-loop systems (MiniMed 780G, Tandem Control-IQ) are recommended as preferred therapy, achieve time-in-range >70% with reduced hypoglycemia.
- •For severe hypoglycemia (unconscious or unable to swallow): give glucagon 1 mg IM or intranasal 3 mg, or IV dextrose 50% 25 g. Recheck in 15 minutes.
- •For conscious hypoglycemia (<70 mg/dL): administer 15-20 g oral glucose (4 oz juice, 3-4 glucose tablets); repeat in 15 minutes if still <70 mg/dL.
- •Anticoagulate with statins in all patients aged ≥40 years, or younger with LDL ≥100 mg/dL, hypertension, smoking, or family history of premature CVD. Target LDL <70 mg/dL.
- •Add ACE inhibitor or ARB when urinary albumin-to-creatinine ratio (UACR) >30 mg/g, regardless of blood pressure, to slow nephropathy progression.
- •Do not use SGLT2 inhibitors as routine adjunct, 3.5-fold increased DKA risk (NNH = 28) and FDA boxed warning; consider only in clinical trials.
- •Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate heart failure in diabetic cardiomyopathy.
- •Do not omit basal insulin during illness or fasting, this is the most common precipitant of DKA. Increase insulin by 20-50% during intercurrent illness.
Board Review — High Yield
- •DCCT/EDIC study, intensive insulin therapy (HbA1c ~7%) reduces retinopathy by 76%, nephropathy by 54%, CVD by 42%; legacy effect persists for decades despite later HbA1c convergence.
- •C-peptide <0.2 nmol/L, distinguishes T1DM (absolute deficiency) from T2DM with high specificity; stimulated C-peptide <0.6 nmol/L confirms severe beta-cell loss.
- •GADA, IA-2A, ZnT8A, ≥1 positive confirms autoimmune etiology; ZnT8A useful in antibody-negative cases and may signal concurrent autoimmune thyroiditis.
- •HLA DR3-DQ2 and DR4-DQ8, strongest genetic risk (OR >20 for heterozygotes); non-HLA loci (PTPN22, INS, CTLA4) contribute modest additive risk.
- •DKA triad, glucose >250 mg/dL, pH <7.3, bicarbonate <15 mEq/L with ketones; treatment: NS 15-20 mL/kg, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, K+ replacement.
- •DO NOT use bicarbonate for DKA unless pH <6.9, no outcome benefit, may worsen hypokalemia and cerebral edema.
- •Advanced hybrid closed-loop (AHCL), preferred therapy; MiniMed 780G and Tandem Control-IQ achieve TIR >70% with fewer hypoglycemic events vs MDI.
- •SGLT2i contraindicated in T1DM, 3.5-fold DKA risk (NNH 28); avoid outside clinical trials despite HbA1c reduction of 0.37%.
- •Autoimmune polyglandular syndrome type 2, Addison disease + T1DM or thyroid disease; screen with TSH, TPO antibodies, tTG-IgA at diagnosis; annual TSH thereafter.
- •Teplizumab (anti-CD3), first FDA-approved disease-modifying therapy; delays progression from Stage 2 to Stage 3 T1DM by ~2 years in at-risk individuals.
Deep Dive — Evidence Details
Definition, Classification and Axis Nomenclature
- ▸T1D is an etiologic and biologic classification, not simply childhood diabetes or insulin-treated diabetes. [245][251][255]
- ▸Adult-onset autoimmune diabetes and LADA belong to the broader T1D spectrum but may differ in β-cell reserve and progression. [245]
- ▸Autoantibody profiles should be interpreted with clinical data, routine laboratory findings, and C-peptide measurements. [245][251]
- ▸Immune endotypes and residual β-cell reserve are useful descriptive axes, but neither is yet a universally standardised standalone classification system. [245][255]
- ▸DKA and chronic complications describe presentation, severity, or burden and should not alone determine diabetes etiology. [8][246][252][256]
- ▸ICD-10 E10 is an administrative label that should be clinically validated. [257]
Definition
Type 1 diabetes mellitus (T1D; also written T1DM) is best defined as a diabetes phenotype characterized primarily by autoimmune disease biology, with classification supported by diabetes-associated autoantibody profiling and clinical context rather than by age alone. Contemporary evidence recognises that T1D is heterogeneous: age at onset, rate of disease progression, immune-cell profiles, and complication risk may differ substantially between individuals. This has led to the proposed concept of distinct T1D endotypes rather than a single uniform disease process. [245][251][255]
The term “type 1 diabetes” should therefore be used as an etiologic and biologic classification, not merely as a synonym for childhood diabetes or insulin treatment. Adult-onset autoimmune diabetes and latent autoimmune diabetes in adults (LADA) are represented within the T1D spectrum in comparative phenotyping research, although their residual β-cell function and clinical evolution may differ from those of classical rapidly progressive disease. [245] The presence of diabetes-associated autoantibodies can support classification, but available evidence also indicates that diagnosis and discrimination are improved when antibody profiles are interpreted together with clinical data and routine laboratory variables. [251]
Classification framework
A practical classification should describe T1D across several complementary axes:
-
Etiologic axis: autoimmune T1D is distinguished from other diabetes phenotypes by evidence of immune-mediated disease, particularly diabetes-associated autoantibodies and compatible clinical findings. [245][249]C[251]
-
Clinical-phenotype axis: T1D may present as classical, typically rapidly progressive autoimmune diabetes or as adult-onset autoimmune diabetes/LADA. These categories should not be treated as interchangeable with type 2 diabetes solely because onset occurs in adulthood or because residual endogenous insulin secretion is initially measurable. [245]
-
β-cell reserve axis: fasting and glucagon-stimulated C-peptide provide measures of residual β-cell secretory reserve. Comparative longitudinal work has specifically evaluated these measures at diagnosis across T1D, LADA, and type 2 diabetes phenotypes, supporting the use of β-cell reserve as a biologic descriptor in addition to the diagnostic label. [245]
-
Immune-endotype axis: differences in peripheral immune-cell profiles and T- and B-cell responses may identify biologically distinct T1D subgroups, particularly in people with longstanding disease. These profiles have also been associated with variation in macrovascular complications, although they are not yet a universally adopted routine classification system. [255]
-
Presentation/severity axis: diabetic ketoacidosis (DKA) is a clinically important presentation or complication of T1D, especially in newly diagnosed pediatric cohorts, but DKA should not be used alone to define the etiologic class because the available evidence addresses it as an acute clinical state rather than as a complete disease taxonomy. [252]
-
Complication axis: retinopathy, diabetic macular edema, nephropathy, neuropathy, and cardiovascular disease describe disease burden and prognosis, not the primary diabetes type. In T1D, diabetic macular edema is recognised as a vision-threatening complication, while microalbuminuria is used as an early marker of diabetic kidney disease and cardiovascular risk is influenced by central adiposity and other factors. [8]A1a[246][256][10]B2b
Axis nomenclature
For consistency, the following nomenclature is recommended: T1D-A for autoimmune T1D when autoimmune evidence is documented; T1D-LADA for adult-onset autoimmune diabetes with a slower clinical course or preserved early β-cell reserve; and T1D-unclassified when the clinical phenotype is compatible with T1D but antibody or β-cell data are unavailable or inconclusive. These labels are descriptive extensions of the evidence base rather than universally validated formal diagnostic codes. [245][251]
Where laboratory information is available, the record should separately report: (a) antibody status and profile; (b) fasting or stimulated C-peptide; (c) age and circumstances of clinical onset; (d) DKA status at presentation; and (e) relevant autoimmune comorbidity. T1D occurs in the context of broader autoimmune clustering, including associations with autoimmune thyroid disease, celiac disease, and other autoimmune disorders. [12]B3b[247]C[249]C
Administrative nomenclature should remain distinct from biologic nomenclature. ICD-10 code E10 is used to identify T1D in hospital-discharge data, but coding accuracy requires clinical validation against accepted diagnostic criteria. [257] A code alone should therefore not replace clinical and laboratory classification.
Boundaries and interpretation
T1D classification is probabilistic when based on incomplete data. Autoantibody results, C-peptide, phenotype, and clinical trajectory should be integrated rather than interpreted in isolation. Predictive models combining autoantibody profiles with routine laboratory and clinical variables have been investigated for differentiating T1D from other diabetes types, but these tools should be regarded as supportive rather than as replacements for clinical diagnosis. [251]
The classification should also avoid conflating associated conditions with defining features. Maternal T1D, mode of conception, offspring atopic dermatitis, androgen excess in women with T1D, and retinal or renal complications may be clinically relevant, but they do not redefine the parent diabetes category. [9]B2b[11]B3b[258][8]A1a[246]
| Axis | Preferred descriptors | Evidence basis |
|---|---|---|
| Etiology | Autoimmune; antibody-positive, antibody-negative, or unavailable | Diabetes-associated autoantibody profiling and clinical integration [249]C[251] |
| Clinical phenotype | Classical T1D; adult-onset autoimmune diabetes; LADA | Comparative phenotype and β-cell-reserve studies [245] |
| β-cell reserve | Preserved, reduced, or markedly depleted fasting/stimulated C-peptide | Fasting and glucagon-stimulated C-peptide assessment [245] |
| Immune biology | Distinct immune-cell or disease endotype profile | Peripheral immune profiling and complication associations [255] |
| Presentation | DKA present or absent; symptomatic or incidentally detected | Pediatric DKA cohort evidence [252] |
| Complication burden | Retinal, renal, neurologic, or cardiovascular involvement | Complication-focused T1D studies [8]A1a[10]B2b[246][256] |
| Administrative coding | ICD-10 E10 | Validated hospital-discharge coding study [257] |
Axis Physiology, Pathophysiology and Biochemical Signature
- ▸T1DM is fundamentally a β-cell failure disorder driven by immune-mediated injury, with C-peptide serving as a marker of residual endogenous secretory reserve. [245][264]
- ▸Qualitative immune activation—including NF-κB, EGFR, MAPK, hypoxia, and TNF-centred pathways—may distinguish rapidly progressive T1DM from more indolent LADA. [264]
- ▸The acute biochemical phenotype may progress from hyperglycaemia and osmotic diuresis to ketogenesis, metabolic acidosis, dehydration, and acute kidney injury during DKA. [41]
- ▸GLP-1RAs may modestly improve HbA1c and reduce insulin requirements, but adjunctive therapy does not replace insulin and DKA risk remains particularly important with SGLT2 inhibitors. [39][40]
- ▸Emerging S1P, gut-brain, lipidomic, ACE2-autoantibody, neuroimaging, and glucagon-signalling findings are mechanistic or exploratory rather than validated diagnostic signatures. [259][260][262][263][266][269]
Physiological axis
Type 1 diabetes mellitus (T1DM) is characterized by immune-mediated injury to pancreatic β-cells, with progressive loss of endogenous insulin secretion and β-cell secretory reserve. The resulting biochemical phenotype is insulin deficiency rather than primary insulin resistance, although substantial heterogeneity exists in the tempo and extent of β-cell failure. [245][264] Residual β-cell function is clinically relevant because fasting and glucagon-stimulated C-peptide provide measures of endogenous insulin secretion and are associated with glycaemic control and long-term outcomes across diabetes phenotypes. [245]
Insulin deficiency disrupts the normal relationship between glucose availability, hepatic glucose production, adipose lipolysis, and ketone-body metabolism. Clinically, this produces hyperglycaemia, glycosuria, osmotic diuresis, polyuria, and dehydration; severe metabolic decompensation may culminate in diabetic ketoacidosis (DKA). The available evidence specifically documents polyuria in children with new-onset T1DM and DKA, and identifies DKA as a frequent context for acute kidney injury in reported paediatric cases. [41]C4 In this setting, the biochemical signature is therefore not limited to elevated glucose: it may include ketonaemia or ketonuria, metabolic acidosis, volume depletion, and impaired renal function. [41]C4
Immune and inflammatory pathophysiology
Autoimmune diabetes is immunologically heterogeneous. Single-cell immune transcriptomics across more than 400,000 peripheral blood mononuclear cells found broadly comparable immune-cell composition among patients with newly diagnosed T1DM, latent autoimmune diabetes in adults (LADA), and healthy controls, suggesting that qualitative immune activation rather than cell-number differences contributes to disease heterogeneity. [264] T1DM showed activation of NF-κB, EGFR, MAPK, and hypoxia-related pathways, with TNF-centred intercellular communication, whereas LADA occupied a more indolent inflammatory set point along a shared autoimmune spectrum. [264]
Additional mechanistic evidence implicates lymphocyte-trafficking and intestinal immune pathways. Integrated clinical and single-cell analyses examined sphingosine-1-phosphate (S1P), its receptor S1PR1, HDL-bound S1P, and apolipoprotein M in T1DM, alongside intestinal transcriptomic changes and non-obese diabetic mouse models. [260] These findings support investigation of S1P signalling and gut-associated immune regulation, but they do not establish a validated diagnostic biochemical threshold or a causal therapeutic target in humans. [260] The gut-brain axis is likewise a proposed contributor to obesity emerging in T1DM; current priorities include gnotobiotic models and targeted metabolomics to distinguish causal microbial metabolites from correlates. [259]
Potential post-infectious immune mechanisms remain investigational. A small study evaluated anti-ACE2 autoantibodies in 35 patients with new-onset T1DM after COVID-19 and 30 recovered controls, motivated by hypotheses involving molecular mimicry, inflammation, and direct β-cell injury. [266]C These data are hypothesis-generating and should not be interpreted as demonstrating that anti-ACE2 antibodies define routine T1DM or explain most cases. [266]C
Metabolic and biochemical signature
The core biochemical signature reflects inadequate insulin action: reduced C-peptide, hyperglycaemia, increased reliance on exogenous insulin, and vulnerability to ketogenesis during illness, insulin interruption, fasting, or other catabolic stress. Direct longitudinal evidence indicates that baseline β-cell secretory reserve differs across diabetes phenotypes and that residual function remains central to disease pathophysiology. [245] Lipid metabolism may also be altered; a pilot clinical and murine lipidomic study identified lipidomic changes associated with cognitive impairment in T1DM, although the findings remain exploratory and do not define a routine diagnostic panel. [262]C
Neurovascular and metabolic consequences extend beyond glucose. Young adults with T1DM demonstrated early and subtle differences in resting-state brain activity and connectivity on functional MRI, while a separate lipidomic study linked specific serum and hippocampal metabolic alterations with mild cognitive impairment. [263][262]C These observations support chronic glycaemic exposure, hypoglycaemia, vascular factors, and altered lipid metabolism as interacting contributors, but the cited studies do not establish a single causal biochemical pathway. [262]C[263]
Pharmacological modulation of the axis
Adjunctive therapies modify downstream metabolic physiology but do not replace insulin in T1DM. A meta-analysis of randomised trials found that GLP-1 receptor agonists (GLP-1RAs) produced modest glycaemic improvement, reducing HbA1c by 0.56%, increasing time in range, and reducing total and basal daily insulin requirements. [40]A1a A cardiometabolic meta-analysis also evaluated GLP-1RAs as adjuncts to insulin in T1DM, including effects on weight and related risk factors. [43]A1a Effects on body composition are clinically relevant: a systematic review including five T1DM studies evaluated GLP-1RA or SGLT2-inhibitor-associated changes in lean body mass, indicating that weight loss should not be equated automatically with loss of adipose tissue alone. [31]A1a
Safety limits the use of these agents. Updated pooled evidence found no significant increase in overall hypoglycaemia with GLP-1RAs (RR 1.01) and no significant increase in severe hypoglycaemia (RR 0.74, low-certainty evidence); serious adverse events were also not increased (RR 0.89). [39]A1a A broader adjunctive-therapy review continued to identify DKA as a central safety concern, particularly for SGLT2 inhibitors, which can promote glycosuria and a catabolic milieu even when glucose elevation is less pronounced. [40]A1a Real-world comparative data from 112 adults—96 receiving GLP-1RAs and 16 SGLT2 inhibitors—provide additional observational information on glycaemia, weight, insulin dose, renal function, and lipids but cannot establish comparative causality. [48]B2b
Glucagon remains a counter-regulatory determinant of hepatic glucose output and ketone metabolism. Pharmacological glucagon-receptor blockade with volagidemab has been studied in healthy participants using exposure-response modelling of glucagon concentrations and fasting plasma glucose; this demonstrates investigational manipulation of glucagon signalling, not an established T1DM treatment. [269]C
Clinical expression and modifiers
Polyuria and adherence-related treatment failure are clinically important expressions of the metabolic axis. Digital interventions have been systematically evaluated for insulin administration, glucose monitoring, HbA1c, satisfaction, and engagement, with effectiveness varying across settings. [42]B2a A 12-week mixed-methods study of 148 adults examined a Bluetooth-enabled glucose-management application versus structured self-monitoring, assessing HbA1c and self-management behaviour. [267] Registry data from 3,600 adults aged 60 years or older identified missed opportunities in risk-reduction therapy and target attainment across US and German/Austrian cohorts. [268] Diabetes may also alter inflammatory responses and wound healing; in a murine spinal implant-infection model, T1DM was compared with T2DM and control animals, including experimental semaglutide treatment. [261] These preclinical findings should not be extrapolated directly to human T1DM management. [261]
| Domain | Evidence-supported signature or implication |
|---|---|
| β-cell reserve | Fasting and glucagon-stimulated C-peptide reflect residual endogenous insulin secretion. [245] |
| Catabolic decompensation | Polyuria, dehydration, ketone production, acidosis, and possible acute kidney injury occur in severe DKA. [41]C4 |
| Immune phenotype | NF-κB, EGFR, MAPK, hypoxia, and TNF-centred activation are reported in T1DM. [264] |
| Lipid and neural consequences | Exploratory lipidomic and functional-MRI abnormalities have been associated with cognitive or brain-function changes. [262]C[263] |
| Treatment-modified physiology | GLP-1RAs reduce HbA1c and insulin requirements; SGLT2 inhibitors and GLP-1RAs may alter body composition. [31]A1a[40]A1a |
Epidemiology, Etiology and Risk Factors
- ▸The supplied studies provide clinical and cohort-based context but do not provide a global incidence or prevalence estimate for T1DM. [270][274][281]
- ▸Autoimmune clustering and immune-mediated mechanisms are the principal etiologic themes supported by the references. [271][274][276]
- ▸Obesity, gut–brain signaling, neonatal vitamin D status, and genetic predictors remain investigational or associative rather than established solitary causes. [135][259][276]
- ▸Immune checkpoint inhibitor exposure, particularly dual therapy, is relevant to the rare ICI-induced T1DM phenotype. [271]
- ▸After diagnosis, intentional insulin omission, disordered eating, hypoglycemia, obstructive sleep apnea, and vascular or renal risk factors modify morbidity rather than cause ordinary T1DM. [74][270][233][280]
Epidemiology
Type 1 diabetes mellitus (T1DM) is represented across pediatric, adolescent, and adult populations in the available 2026 evidence. Pediatric cohorts include children and adolescents followed in tertiary-care settings, including a cohort of 639 patients with T1DM evaluated for additional autoimmune disease and a Saudi Arabian cohort of 449 patients aged ≥9 years assessed for diabetic retinopathy. [274][82]B3b Adolescents are also a clinically important population for hypoglycemia and disordered eating; a Chinese quasi-experimental study included 110 adolescents with T1DM, while a Spanish nationwide study included 451 people aged ≥16 years. [270][281] These studies are not population-based estimates of T1DM incidence or prevalence and should not be generalized to national or global epidemiology. [270][274][281]
T1DM is associated with substantial heterogeneity in age at diagnosis and clinical context. Adult-onset T1DM was examined separately from type 2 diabetes in a U.S. propensity-matched cohort, emphasizing that clinically diagnosed T1DM also occurs in adulthood and may have distinct long-term cardiovascular risk patterns. [275]C A separate Korean nationwide study evaluated established T1DM in relation to Parkinson disease, illustrating the use of large administrative datasets to study less common outcomes in people with T1DM. [279]
Etiology and pathophysiologic context
The supplied evidence supports an autoimmune context for T1DM but does not provide a complete account of its initiating causes. Children and adolescents with T1DM were specifically studied for additional autoimmune diseases, and neonatal vitamin D status was investigated in relation to T1DM among nine autoimmune disorders in a Danish population-based cohort. [274][276]C The vitamin D study assessed neonatal 25-hydroxyvitamin D, vitamin D-binding protein, and corresponding genetic predictors; the available abstract does not establish a causal or directional association with T1DM. [276]C
Immune checkpoint inhibitor–induced T1DM represents a distinct, treatment-associated form of diabetes caused by immune activation during cancer therapy. A 2026 systematic review and meta-analysis characterized it as rare but potentially life-threatening, and evaluated incidence, diabetic ketoacidosis (DKA), dual versus monotherapy immune-checkpoint-inhibitor exposure, pre-existing diabetes, and prognostic outcomes. [271] Because this evidence concerns adults receiving immune checkpoint inhibitors, it should not be extrapolated to the usual autoimmune pathogenesis of spontaneous T1DM. [271]
The gut–brain axis and obesity are emerging research areas rather than established causes. A 2026 perspective described the role of the gut–brain axis in obesity and T1DM as requiring mechanistic studies capable of distinguishing correlation from causation. [259] A pediatric systematic review examined the possible bidirectional relationship between obesity and T1DM, including whether childhood obesity is associated with T1DM risk and how weight trajectories after diagnosis relate to metabolic outcomes. [135]B2a The available evidence therefore supports investigation of obesity and metabolic environment as possible modifiers, but does not establish obesity as a sufficient cause of T1DM. [135]B2a[259]
Risk factors and associated conditions
Potential susceptibility factors include autoimmune predisposition, genetic background, and environmental exposures. The Danish cohort evaluated both neonatal biomarkers and genetic predictors in relation to autoimmune disorders including T1DM, while the obesity review assessed observational and interventional pediatric evidence published from January 2010 to January 2026. [276]C[135]B2a Neither supplied abstract establishes a single predictive threshold or a deterministic exposure–disease relationship. [135]B2a[276]C
Pre-existing diabetes and the intensity of immune-checkpoint-inhibitor exposure are relevant risk variables for ICI-associated T1DM; the meta-analysis specifically compared dual therapy with monotherapy and assessed pre-existing diabetes as a potential modifier. [271] These factors apply to treatment-induced disease and not necessarily to spontaneous T1DM. [271]
Once T1DM is established, diabetes-related behaviors and comorbidities influence clinical risk. Intentional insulin omission (“diabulimia”) occurs mainly in adolescents and young adults and is associated with eating-disorder psychopathology, DKA, microvascular complications, and increased mortality. [74]D5 In adults, disordered eating behaviors were evaluated using the Diabetes Eating Problems Survey–Revised, with a positive screening threshold of ≥20 in the Spanish D1ANAS study. [281] Adolescents with T1DM are also vulnerable to recurrent and burdensome hypoglycemia; the Chinese WIKAP study evaluated whether nurse-led web-based education could improve coping confidence and reduce hypoglycemia events. [270]
Several supplied studies identify factors associated with complications rather than with the development of T1DM. High-risk obstructive sleep apnea was examined in 102 adults with T1DM and compared with 126 controls in relation to microvascular complications. [233]B3b Diabetic retinopathy incidence and demographic or systemic predictors were assessed in Saudi Arabia, while urinary podocalyxin and related biomarkers were investigated as early indicators of kidney injury and long-term diabetic kidney disease risk in youth. [82]B3b[280]C Maternal T1DM was studied in relation to adverse pregnancy outcomes in Norway and atopic dermatitis in offspring in Israel; these findings concern consequences or intergenerational associations, not proven causes of maternal T1DM. [277][9]B2b
T1DM is also associated with broader comorbidity patterns. Dental caries and periodontal status in children and adolescents with T1DM were summarized in an umbrella review, and female sexual dysfunction was synthesized in a systematic review and meta-analysis. [73]B2a[273]C Adult-onset T1DM was compared with type 2 diabetes for long-term major adverse cardiovascular and cerebrovascular events, and T1DM was associated with increased Parkinson disease risk in a Korean nationwide nested case-control study. [275]C[279] Autoimmune disease relationships were also examined in people with polycystic ovary syndrome, although that study does not establish PCOS as a risk factor for T1DM. [278]
Clinical interpretation
The strongest etiologic signal in the supplied evidence is immune-mediated disease, including conventional autoimmune clustering and the rare treatment-associated ICI-T1DM phenotype. [271][274][276]C Obesity, gut–brain signaling, neonatal vitamin D status, genetics, and environmental exposures remain areas of association research rather than confirmed solitary causes. [135]B2a[259][276]C Risk assessment should distinguish factors for developing T1DM from factors that modify outcomes after diagnosis, particularly insulin omission, disordered eating, hypoglycemia, sleep apnea, and vascular or renal complications. [74]D5[270][233]B3b[280]C
| Domain | Evidence from supplied references | Interpretation |
|---|---|---|
| Autoimmunity | Additional autoimmune disease in pediatric T1DM; neonatal vitamin D, binding protein, and genetic predictors studied across autoimmune disorders | Supports autoimmune susceptibility, but no single causal biomarker is established. [274][276]C |
| Treatment-associated disease | Immune checkpoint inhibitors; dual versus monotherapy and pre-existing diabetes evaluated | Applies to rare ICI-T1DM, not necessarily spontaneous T1DM. [271] |
| Obesity and metabolism | Pediatric review of obesity, T1DM risk, and post-diagnosis weight trajectories | Possible bidirectional association; causality remains unresolved. [135]B2a |
| Behavioral modifiers | Intentional insulin omission and disordered eating; DEPS-R positive threshold ≥20 | Important post-diagnosis risks for DKA and adverse outcomes. [74]D5[281] |
| Complication modifiers | Hypoglycemia, obstructive sleep apnea, retinopathy, and kidney injury biomarkers | Influence morbidity after T1DM is established. [270][233]B3b[82]B3b[280]C |
Clinical Presentation
- ▸T1DM may present with symptomatic hyperglycemia, DKA, screening-detected disease, or an atypical extra-pancreatic manifestation. [283][290][293]
- ▸DKA remains possible after diagnosis and can occur despite continuous glucose monitoring, insulin pumps, or automated insulin delivery. [285]
- ▸Severe DKA may include vomiting, abdominal pain, diarrhea, altered consciousness, deep breathing, and marked acidosis; persistent abdominal findings require evaluation for another emergency. [286][287]
- ▸Overweight or obesity and negative diabetes-associated autoantibodies do not exclude pediatric T1DM. [283][284]
- ▸Unexplained bilateral cataracts, recurrent infections, edema, hepatomegaly, seizures, or other autoimmune findings may be presenting clues or associated manifestations. [91][93][95][96][289]
- ▸Glucose-monitoring displays can be misunderstood; interpretation should be linked to symptoms, trends, insulin administration, and metabolic assessment. [282]
Overview
Type 1 diabetes mellitus (T1DM) has a heterogeneous clinical presentation. It may be recognized through symptomatic hyperglycemia, diabetic ketoacidosis (DKA), screening-detected dysglycemia, or an unusual diabetes-associated manifestation. The available updated evidence includes pediatric and adult cohorts, retrospective studies, systematic reviews, and case reports; therefore, findings from individual reports should not be generalized to all people with T1DM. [283][293]D
Initial presentation and metabolic decompensation
New-onset T1DM in children may present with DKA, and recent pediatric research has examined factors associated with DKA presence, severity, and residual β-cell function at diagnosis. [290]D In a German multicenter study of 203 adult DKA episodes, 14% occurred in adults with newly diagnosed T1DM and 64% occurred in people with pre-existing T1DM. DKA also occurred despite continuous glucose monitoring in 51% of pre-existing T1DM cases and despite insulin pumps or automated insulin-delivery systems in 24%, demonstrating that technology does not eliminate the risk of acute metabolic decompensation. [285]C
DKA commonly produces gastrointestinal and systemic symptoms, including abdominal pain, vomiting, diarrhea, weakness, altered consciousness, and abnormal breathing. In a reported severe case after insulin omission, a 30-year-old woman presented with diarrhea, vomiting, and stupor, with glucose 1,869 mg/dL, arterial pH 6.83, and bicarbonate 2.2 mmol/L. [287]D Abdominal pain and gastrointestinal symptoms may improve as DKA resolves; persistent or worsening abdominal findings should raise concern for a concurrent intra-abdominal emergency, such as intestinal ischemia. [287]D A case of recurrent DKA in an adolescent with poor insulin adherence featured abdominal pain, vomiting, mild weakness, slightly increased deep regular respirations, cool extremities, diminished pedal pulses, and hepatomegaly, illustrating that recurrent metabolic crises may coexist with chronic complications or syndromic features. [286]C
Euthyroid sick syndrome is also reported during pediatric DKA. In a retrospective cohort of 182 children with T1DM admitted for DKA, thyroid-stimulating hormone, free thyroxine, and free triiodothyronine were measured at presentation and again 2 weeks after DKA resolution to characterize prevalence, hormonal patterns, and recovery. [92]B2b
Body habitus and biochemical phenotype
Although T1DM classically presents in lean individuals, excess body weight may modify the presentation. In a Hungarian pediatric cohort of 994 children diagnosed between 2014 and 2023, patients were categorized by BMI z-score as normal weight, overweight, or obese to evaluate differences in metabolic presentation. [284] The study specifically addressed the increasing coexistence of childhood overweight or obesity and T1DM and their potential effects on autoimmune disease expression and complications. [284] Consequently, overweight or obesity should not by itself exclude T1DM from the differential diagnosis. [284]
Autoantibody status is also variable. In a Dutch pediatric cohort of 562 patients diagnosed before age 18 years, antibody-positive T1DM was defined by positivity for one or more of GADA, IA-2A, ZnT8A, IAA, or ICA, while patients solely positive for anti-ICA were excluded. [283] The study investigated clinical and biochemical differences between autoantibody-positive and autoantibody-negative disease, indicating that a minority of children may have a T1DM phenotype without the commonly measured diabetes-associated autoantibodies. [283]
Atypical and associated manifestations
T1DM may occasionally be recognized through an extra-pancreatic manifestation. Bilateral cataracts preceded the diagnosis in three children with T1DM, supporting diabetes screening in children with otherwise unexplained cataracts even when systemic symptoms are absent. [96]C4 Severe or longstanding poorly controlled T1DM may be associated with Mauriac syndrome; one adolescent with more than six years of T1DM had recurrent DKA, irregular meals, inconsistent glucose monitoring, poor insulin adherence, abdominal symptoms, hepatomegaly, and physical findings compatible with severe metabolic illness. [286]C
Renal or infectious presentations may complicate the clinical picture. A patient with a 19-year history of poorly controlled T1DM presented with nausea, vomiting, and generalized edema in association with proliferative glomerulonephritis with monoclonal IgG1-κ deposition; she had recently experienced fever and a urinary tract infection followed by recurrent fever. [93]C4 Pediatric emphysematous pyelonephritis is rare but life-threatening; in a systematic review of 21 cases, reflux or obstructive nephropathy was the major risk factor in 52.3%, and the median age at presentation was 48 months. [91]C4
T1DM can coexist with other autoimmune or immune-mediated disorders. A review of 78 patients with T1DM and GAD-antibody-associated autoimmune encephalitis-associated epilepsy or seizures found that T1DM preceded the neurological syndrome in 40%, followed it in 29%, and overlapped with it in 9%; age at first presentation ranged from 1 to 72 years. [289]D T1DM may also occur as part of autoimmune polyglandular syndrome type 1, in which hypoparathyroidism, vitiligo, anemia, chronic diarrhea, and islet autoimmunity may coexist; one reported patient initially presented with hypocalcemic convulsions. [95]C4
Clinical interpretation and safety
Glucose-monitoring data may be misinterpreted by people with T1DM, leading to inaccurate treatment decisions and increased hospitalization risk. A randomized mixed-methods evaluation therefore tested systems that add textual descriptions to glucose data, with the goal of reducing interpretation effort and improving self-management and HbA1c. [282] Clinical assessment should integrate symptoms, glucose trends, ketone or acid–base status when indicated, insulin use, adherence, comorbid autoimmune disease, and possible alternative diagnoses rather than relying on a single glucose value or device display. [282][285]C[287]D[293]D
| Presentation pattern | Illustrative findings | Reference |
|---|---|---|
| DKA at or after diagnosis | Vomiting, abdominal pain, diarrhea, stupor, deep breathing, severe acidosis; may occur despite diabetes technology | [285]C[286]C[287]D |
| Modified metabolic phenotype | Pediatric T1DM with overweight or obesity | [284] |
| Autoantibody-negative phenotype | Clinical and biochemical T1DM without the usual measured islet autoantibodies | [283] |
| Atypical presenting sign | Bilateral cataracts preceding diabetes diagnosis | [96]C4 |
| Associated autoimmune or systemic disease | Seizures/encephalitis, polyglandular autoimmunity, renal disease, or severe infection | [91]C4[93]C4[95]C4[289]D |
Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
- ▸The supplied references provide no validated protocol for diagnosing T1D with paired hormone measurements, dynamic endocrine testing, or anatomical localization [131][94].
- ▸Transient GADA positivity in a child with mild fasting hyperglycaemia, overweight, insulin resistance, and a family history of diabetes illustrates why antibody results must be interpreted with phenotype and persistence [94].
- ▸Additional autoimmune disease is common enough in pediatric T1D cohorts to justify structured comorbidity assessment, although the cited study does not establish a hormone-based diagnostic algorithm [274].
- ▸Thyroid elastography has been studied in antibody-negative children with T1D or celiac disease, but the available evidence does not establish a diagnostic cutoff or replacement for standard evaluation [296].
- ▸DKA and atypical complications such as mucormycosis require urgent, clinically directed assessment; neither is an indication for routine endocrine dynamic testing or pancreatic localization [286][300].
Scope of the available evidence
The supplied references do not provide a contemporary diagnostic algorithm for type 1 diabetes mellitus (T1D) based on paired hormone measurements, dynamic endocrine testing, or anatomical localization. Most address treatment, complications, comorbid autoimmunity, or unrelated differential diagnoses rather than the initial biochemical confirmation of T1D. The randomized-trial meta-analysis of automated insulin delivery in children younger than 7 years evaluated continuous-glucose-monitoring outcomes, glycated haemoglobin, insulin dose, severe hypoglycaemia, and diabetic ketoacidosis (DKA), not diagnostic testing [131]A1a. Similarly, studies of glycaemic control, obesity, cardiovascular risk, retinopathy, kidney disease, neuroimaging, and self-management do not validate paired hormones, stimulation/suppression tests, or imaging for localizing pancreatic autoimmune disease [135]B2a[275]C[82]B3b[295][294]C[263][297]C[298].
Biochemical classification and differential diagnosis
Within this evidence set, the most direct diagnostic lesson comes from a pediatric case of a pathogenic-appearing glucokinase variant. The child had mild fasting hyperglycaemia, a paternal history of type 2 diabetes, overweight with marked insulin resistance, and initially positive—but subsequently transient—glutamic acid decarboxylase antibodies (GADA); the authors used the case to emphasize differentiation of GCK-related monogenic diabetes from T1D and type 2 diabetes [94]C4. Accordingly, antibody positivity should be interpreted with the clinical phenotype and persistence of the result rather than treated as an isolated localization test; this conclusion is limited to the reported case and cannot establish population-level test performance [94]C4. The supplied references contain no comparative data for C-peptide, stimulated C-peptide, insulin, proinsulin, glucagon, cortisol, growth hormone, or other paired hormone panels in suspected T1D [94]C4[131]A1a.
Obesity does not, by itself, resolve the diagnostic classification: the pediatric systematic review specifically examined the association between obesity and T1D risk, post-diagnostic weight trajectories, and metabolic outcomes, but the supplied abstract does not provide a diagnostic threshold or a validated hormone-based discriminator [135]B2a. Therefore, the evidence provided here supports a phenotype-driven differential diagnosis, but not a rule that obesity excludes T1D or that insulin resistance proves type 2 diabetes [135]B2a.
Autoimmune assessment and associated disease
Children and adolescents with T1D have an increased risk of additional autoimmune diseases; a retrospective cohort of 639 patients assessed the prevalence, spectrum, timing, clinical characteristics, and associated factors of these conditions using clinical, laboratory, and autoantibody data [274]. This supports incorporating autoimmune comorbidity assessment into the broader workup, although the supplied abstract does not specify a paired-hormone protocol or establish that screening results confirm T1D [274].
Thyroid disease is particularly relevant to ancillary evaluation. A pediatric study examined shear-wave thyroid elastography in children with T1D or celiac disease who had negative thyroid autoantibodies, evaluating whether tissue elasticity could identify autoimmune thyroiditis despite seronegativity [296]. The study was cross-sectional and single-center; its abstract does not provide a diagnostic cutoff, sensitivity, specificity, or evidence that elastography should replace thyroid biochemical or antibody testing [296]. Pediatric celiac disease is also frequently associated with other immune-mediated conditions, and a five-year single-center study applied the 2020 ESPGHAN diagnostic criteria, including non-biopsy confirmation in selected children [299]C. These findings support targeted evaluation for associated autoimmune disease, not dynamic endocrine testing or anatomical localization of T1D [274][296][299]C.
Acute presentation and complication-directed testing
DKA remains clinically important in T1D: a case of a 14-year-old with recurrent DKA described abdominal pain, vomiting, deep regular breathing, poor insulin adherence, and hepatomegaly in the context of Mauriac syndrome [286]C. Another adolescent with T1D developed rhino-orbital-cerebral mucormycosis after DKA; the report emphasizes that early symptoms may be insidious or atypical and that diagnosis requires attention to the clinical course [300]C. These reports support urgent metabolic and complication-directed assessment when DKA or invasive infection is suspected, but they do not validate hormone-dynamic tests or routine localization imaging for T1D [286]C[300]C.
Renal abnormalities should not automatically be attributed to diabetic kidney disease. Although microalbuminuria was described as the current diagnostic and staging standard in a pediatric biomarker study, urinary fatty acid-binding protein 1 (FABP1) was investigated as a possible marker of earlier tubular injury in 90 children divided into T1D with diabetic kidney disease, T1D without diabetic kidney disease, and controls [295]. A case of proliferative glomerulonephritis with monoclonal IgG1-κ deposition in a woman with a 19-year T1D history illustrates an alternative renal diagnosis requiring disease-specific evaluation [93]C4. Neither study supports paired hormone testing or pancreatic localization [295][93]C4.
Practical conclusion
On the supplied evidence, paired hormone assays, dynamic stimulation or suppression tests, and anatomical localization should not be presented as established components of routine T1D diagnosis. The defensible workup is clinical and biochemical classification, careful interpretation of diabetes-related autoantibodies in context, consideration of monogenic or type 2 diabetes when the phenotype is atypical, and evaluation for associated autoimmune disease or acute complications when clinically indicated [94]C4[135]B2a[274][286]C[296][299]C[300]C. The remaining references concern AID efficacy and safety, dyslipidaemia, cardiovascular outcomes, retinopathy, brain changes, self-management, obesity, or experimental infection biology; they provide no evidence that paired hormones, dynamic testing, or localization improves T1D diagnosis [131]A1a[135]B2a[234]C4[275]C[82]B3b[261][263][294]C[297]C[298].
| Approach | Evidence from the supplied references | Role in this section |
|---|---|---|
| Paired hormone assays | No cited study evaluates paired insulin, C-peptide, proinsulin, glucagon, cortisol, or other hormone panels for T1D diagnosis [94]C4[131]A1a | Not established |
| Dynamic endocrine testing | No cited study validates stimulation or suppression testing for T1D classification [131]A1a[135]B2a | Not established |
| Anatomical localization | No cited study supports pancreatic imaging or localization to diagnose routine T1D [131]A1a[274] | Not established |
| Autoantibody interpretation | Transient GADA positivity occurred in a child with a phenotype suggestive of monogenic or type 2 diabetes [94]C4 | Interpret in clinical context |
| Associated-autoimmune evaluation | Pediatric cohorts address thyroid, celiac, and other autoimmune disease in or alongside T1D [274][296][299]C | Clinically relevant ancillary workup |
| Acute complication assessment | DKA-associated presentations and mucormycosis cases require urgent clinical evaluation [286]C[300]C | Indication-driven assessment |
Severity, Staging and Risk Stratification
- ▸Severity assessment should integrate DKA or AKI at presentation, hypoglycaemia risk, residual C-peptide, glycaemic exposure, and chronic complications. [149][245][304]
- ▸No universally accepted TRD classification exists; the proposed T1DM-specific system remains investigational pending external validation. [244]
- ▸Microalbuminuria remains the current DKD diagnostic and staging standard, while FABP1, TyG, eGDR, and vascular imaging are investigational or adjunctive risk markers. [295][301][302][308]
- ▸Autoantibody status supports phenotypic classification and risk prediction but does not independently define disease severity. [145][283]
- ▸The supplied abstracts do not provide numerical UACR, DKA, DR, DKD, hypoglycaemia, or TRD stage cut-offs; these should not be inferred from the cited studies. [82][149][244][295][301][304]
Overview
Type 1 diabetes mellitus (T1DM) severity is not defined by glycaemia alone. A clinically useful assessment combines acute metabolic instability, residual β-cell function, glycaemic exposure, vascular risk, and established microvascular or macrovascular complications. The available evidence supports a multidimensional approach rather than a single universally accepted staging system. [245][149]B2b[308]
Acute metabolic severity
At diagnosis, diabetic ketoacidosis (DKA) and acute kidney injury (AKI) are important markers of acute metabolic and renal severity in children. A cohort of 153 children with newly diagnosed T1DM specifically evaluated cortisol responses in relation to DKA, AKI, biochemical abnormalities, and renal parameters, supporting consideration of both metabolic and kidney involvement when characterising initial severity. [304] The supplied evidence does not provide the study’s numerical DKA or AKI thresholds; therefore, those cut-offs should be taken from the applicable paediatric diagnostic guideline rather than inferred from this cohort. [304]
Hypoglycaemia represents a separate dimension of severity and may occur during hospitalisation even in adults with established T1DM. A multicentre Chinese study developed and externally validated an interpretable machine-learning model for in-hospital hypoglycaemia using 1,048 development patients and a 7:3 development–validation split from adults treated in five tertiary hospitals between 2019 and 2025. [149]B2b The abstract identifies the model as a risk-prediction tool but does not provide the final predictor coefficients or a bedside score; it should therefore complement, not replace, clinical assessment. [149]B2b
β-cell reserve and disease phenotype
Residual β-cell secretory reserve is relevant to severity stratification because it reflects endogenous insulin production and may influence glycaemic control and long-term outcomes. In a prospective observational study of 393 adults with newly diagnosed diabetes, fasting and glucagon-stimulated C-peptide were measured at diagnosis across diabetes phenotypes, including classical adult-onset autoimmune diabetes and latent autoimmune diabetes in adults (LADA); 89 participants were reassessed after a mean of seven years. [245] Follow-up glucagon stimulation was not repeated in participants with T1DM or LADA, limiting conclusions about longitudinal reserve in these groups. [245]
Autoantibody status can refine phenotypic classification but does not by itself establish clinical severity. In a Dutch paediatric cohort of 562 patients diagnosed before age 18 years, autoantibody-positive disease was defined by positivity for one or more of GADA, IA2A, ZnT8, IAA, or ICA, while patients solely positive for anti-ICA were excluded. [283] Autoantibody-negative T1DM therefore represents a clinically relevant subgroup requiring careful confirmation of diagnosis and consideration of alternative or monogenic diabetes, although the supplied abstract does not provide outcome-based severity thresholds. [283] In first-degree relatives aged 2–18 years, screening for ZnT8A, GADA, IAA, and IA-2A provides risk identification before clinical disease; this is prediction of diabetes risk, not staging of established T1DM. [145]C4
Chronic complication staging
Kidney disease should be staged using albuminuria and kidney function, with both persistent urinary albumin-to-creatinine ratio (UACR) elevation and estimated glomerular filtration rate considered. Microalbuminuria remains the current diagnostic and staging standard for diabetic kidney disease (DKD), although it may reflect established renal injury rather than the earliest tubular changes. [295] In children with T1DM, urinary FABP1 was investigated as a marker of proximal tubular injury in a case-control study comprising 30 participants with DKD, 30 without DKD, and 30 controls; it is promising as an adjunctive biomarker but is not established as a replacement for albuminuria-based staging. [295] In adults, a retrospective study of 210 patients found that the triglyceride-glucose index was associated with DKD, while a separate study of 263 adults with T1DM evaluated estimated glucose disposal rate (eGDR) as a surrogate of insulin resistance and its relationship with microvascular complications. [302][308] These markers may support risk stratification, but the supplied evidence does not establish validated universal cut-offs.
Vascular risk may be detectable before conventional carotid intima-media thickening. Among 283 adolescents with T1DM and 106 matched controls, low-grade albuminuria was evaluated alongside a carotid or common femoral artery triple-line pattern as a marker of peripheral vascular remodelling. [301] The study suggests that UACR and femoral vascular imaging may identify early endothelial or arterial changes, but the abstract does not provide numerical UACR thresholds or a validated clinical stage. [301]
Retinopathy and advanced ocular disease
Diabetic retinopathy (DR) risk should incorporate diabetes duration, glycaemic exposure, and the presence and anatomical extent of retinal disease. A retrospective Saudi Arabian cohort followed 449 patients aged ≥9 years with T1DM from 2015 to 2025 to estimate DR incidence and associated demographic and systemic predictors. [82]B3b The supplied abstract does not report the incidence estimate or specific independent predictors; consequently, it supports regional risk surveillance but not a new severity threshold. [82]B3b
For advanced proliferative disease, tractional retinal detachment (TRD) and combined tractional rhegmatogenous retinal detachment (TRRD) represent high-severity phenotypes requiring specialist vitreoretinal assessment. A 2026 retrospective cohort evaluated pars plana vitrectomy outcomes in young patients with T1DM, examined tamponade selection, assessed outer-retinal biomarkers, and proposed a TRD staging system because no universally accepted classification system currently exists. [244] The proposed system should be regarded as investigational until externally validated; the supplied abstract does not provide the individual stage definitions or outcome thresholds. [244]
Additional risk modifiers
Poor metabolic control and more frequent hyperglycaemia were associated with impaired epidermal barrier measures, including transepidermal water loss and epidermal hydration, in 125 children and adolescents with T1DM aged 6–18 years. [303] Plantar-fascia thickness was studied in 290 adults with T1DM as a possible correlate of advanced glycation and diabetic peripheral neuropathy, while advanced glycation products and sclerostin were examined in relation to skeletal outcomes across diabetes phenotypes. [256][306] Periodontal disease in adolescents with T1DM was associated with distinct oral-microbiome profiles in a 60-participant study. [307] These findings identify potential complication markers but do not constitute validated staging systems. Maternal T1DM was also examined as a population-level risk factor for atopic dermatitis in offspring, and is not a marker of T1DM severity in the mother or child. [9]B2b Emphysematous pyelonephritis remains a rare, life-threatening renal infection in children, most often associated with reflux or obstructive nephropathy rather than routine T1DM staging. [91]C4
| Domain | Evidence-supported assessment | Interpretation |
|---|---|---|
| Acute metabolic | DKA, AKI, biochemical and renal parameters at diagnosis [304] | Acute presentation severity |
| Glycaemic safety | In-hospital hypoglycaemia prediction in adults [149]B2b | Immediate treatment-related risk |
| β-cell reserve | Fasting and glucagon-stimulated C-peptide [245] | Endogenous insulin-production phenotype |
| Kidney disease | Persistent UACR, eGFR; FABP1 as investigational adjunct [295] | DKD diagnosis and staging |
| Vascular disease | UACR and femoral/carotid triple-line pattern [301] | Possible early remodelling |
| Retinopathy | DR surveillance; TRD/TRRD anatomical assessment [82]B3b[244] | Progressive to sight-threatening disease |
| Insulin resistance | TyG index and eGDR [302][308] | Adjunctive cardiometabolic risk stratification |
Acute Management and Endocrine Emergencies
- ▸The supplied evidence does not provide a complete DKA or severe-hypoglycaemia treatment protocol. [39][74][131][166][286][300]
- ▸Intentional insulin omission is associated with DKA and other serious outcomes, particularly in adolescents and young adults. [74]
- ▸DKA may coexist with invasive mucormycosis or other serious disease; atypical symptoms require broad clinical assessment. [93][300]
- ▸AID trials in children younger than 7 years assess TIR at 70–180 mg/dL and include severe hypoglycaemia and DKA as safety outcomes, but pooled results are unavailable in the supplied abstract. [131]
- ▸Perioperative AID evidence from the supplied pilot trial excluded type 1 diabetes and should not be extrapolated. [309]
- ▸GLP-1 receptor agonist meta-analysis findings do not support their use as emergency treatment or unsupervised insulin reduction. [39]
- ▸Evidence supplied for SGLT2 inhibitors and gamma-secretase inhibitors is insufficient to define management during acute illness or suspected DKA. [310][311]
Scope and immediate priorities
This section is restricted to evidence in the supplied reference set and therefore does not replace institution-specific protocols for diabetic ketoacidosis (DKA), severe hypoglycaemia, perioperative insulin administration, or toxic-metabolic emergencies. The available evidence is predominantly systematic-review, cohort, pilot-trial, case-series, and case-report evidence rather than protocol-comparison evidence. [39]A1a[131]A1a[166]B2b[312]C
Diabetic ketoacidosis and insulin omission
DKA remains a clinically important emergency in people with type 1 diabetes, but the supplied references do not provide a complete fluid, insulin, electrolyte, potassium, bicarbonate, cerebral-oedema, or transition-to-subcutaneous-insulin protocol. [39]A1a[74]D5[286]C[300]C Intentional insulin omission, sometimes termed “diabulimia,” is described as a high-risk behaviour occurring mainly in adolescents and young adults; reported consequences include DKA, microvascular complications, and increased mortality. [74]D5 Recurrent DKA, irregular meals, inconsistent glucose monitoring, and poor insulin adherence were present in the reported 14-year-old patient with Mauriac syndrome, who presented with abdominal pain, vomiting, weakness, and mildly deep, regular breathing. [286]C
DKA may be complicated by invasive infection. A case report described rhino-orbital-cerebral mucormycosis after DKA in a 14-year-old girl with type 1 diabetes; the report emphasised rapid progression, high mortality and disability, potential for atypical early symptoms, and the need for multidisciplinary diagnostic and pharmacological management. [300]C In a patient with long-standing type 1 diabetes, nausea, vomiting, oedema, and renal dysfunction were associated with proliferative glomerulonephritis with monoclonal IgG1-κ deposition, illustrating that gastrointestinal symptoms during acute metabolic deterioration may have causes other than uncomplicated DKA. [93]C4
Glucose monitoring, hypoglycaemia, and automated insulin delivery
A nationwide Korean cohort of children and adolescents younger than 19 years with type 1 diabetes evaluated associations between continuous glucose monitoring (CGM) use and DKA or severe hypoglycaemia using adjusted time-to-event analyses; the supplied abstract does not provide the numerical outcome estimates, so CGM should not be presented from this reference as definitively preventing either emergency. [166]B2b A 2026 systematic review and meta-analysis included four randomized controlled trials involving 292 children younger than 7 years and assessed automated insulin delivery (AID) against standard care. [131]A1a Its prespecified efficacy outcome was CGM time in range (TIR) of 70–180 mg/dL, with HbA1c, additional CGM metrics, insulin dose, severe hypoglycaemia, and DKA as secondary or safety outcomes; the supplied abstract is truncated before the pooled efficacy and safety results. [131]A1a
Accordingly, AID or CGM may be considered relevant technologies for reducing exposure to dysglycaemia in very young children, but neither should be relied upon as a substitute for ketone assessment, sick-day planning, reliable insulin delivery, or emergency evaluation when DKA is suspected. The latter management principles are clinical safeguards rather than conclusions established by the supplied abstracts. [131]A1a[166]B2b
Perioperative and acute-care glycaemic management
The supplied perioperative AID trial did not study people with type 1 diabetes: it was an open-label, single-centre pilot randomized trial in patients with diabetes, explicitly excluding type 1 diabetes, who underwent elective surgery and were assigned to an open-source hybrid closed-loop system or a conventional insulin pump. [309] Its findings therefore should not be extrapolated to type 1 diabetes without additional evidence. A separate single-centre case series described an institutional six-phase intraoperative glycaemic algorithm during simultaneous pancreas–kidney transplantation in 11 patients with type 1 or type 2 diabetes and end-stage renal disease, but this is low-level evidence and does not establish a general perioperative protocol. [312]C
Adjunctive agents and ketoacidosis risk
GLP-1 receptor agonists have been investigated as adjuncts to insulin in type 1 diabetes. A systematic review and meta-analysis of 25 studies found a neutral pooled risk for overall hypoglycaemia (RR 1.01, moderate certainty) and no significant increase in severe hypoglycaemia (reported RR 0.74, low certainty) or serious adverse events (RR 0.89, moderate certainty); the supplied abstract notes that DKA concerns remain relevant but does not provide the complete DKA estimate. [39]A1a They should therefore not be used as emergency treatment for DKA or hypoglycaemia, and their safety data do not justify insulin reduction without specialist supervision. [39]A1a
SGLT2 inhibitors were evaluated as adjuncts to insulin in type 1 diabetes in a fracture-risk meta-analysis, but the supplied abstract does not provide pooled DKA or glycaemic-management results. [310] The evidence supplied here is therefore insufficient to define their role during acute illness or to support continuation during suspected DKA. [310] A case report of gamma-secretase inhibitor therapy described glycaemic variability in a person with type 1 diabetes and noted glycosuria in approximately five participants in the phase 3 DeFi trial; this observation supports medication-specific glucose surveillance but does not establish an emergency treatment algorithm. [311]
Other endocrine emergencies and precipitating conditions
Immune checkpoint inhibitor–induced type 1 diabetes is characterised as a rare, potentially life-threatening endocrine immune-related adverse event; a systematic review and meta-analysis evaluated incidence, DKA occurrence, treatment exposure, and prognostic associations, but the supplied abstract does not include the pooled numerical estimates. [271] New hyperglycaemia, ketosis, or DKA during immune checkpoint inhibitor therapy should therefore prompt assessment for treatment-related insulin deficiency alongside usual precipitating causes. [271]
The remaining supplied studies concern exercise-related cardiovascular and glycaemic responses, prenatal autoimmune exposure, autoantibody screening, retinal surgery, postoperative complications, infection models, childhood leukaemia, and musculoskeletal outcomes; they do not establish acute treatment thresholds for DKA, hypoglycaemia, or endocrine crisis. [162]A1b[165]B2b[145]C4[244][261][313][314]
Practical safety statement
In suspected DKA, severe hypoglycaemia, or acute medication-associated dysglycaemia, emergency assessment should be guided by local protocols, with particular attention to insulin omission, infection, immune checkpoint inhibitor exposure, adjunctive glucose-lowering drugs, and the possibility of non-DKA causes of vomiting or renal deterioration. [39]A1a[74]D5[93]C4[271][286]C[300]C[310][311]
| Clinical issue | Evidence in supplied references | Limitation |
|---|---|---|
| DKA and insulin omission | Intentional insulin omission is linked with DKA; recurrent DKA and poor adherence featured in a Mauriac syndrome case. [74]D5[286]C | No protocol-level treatment evidence. [74]D5[286]C |
| CGM/AID | AID RCT meta-analysis in children <7 years used TIR 70–180 mg/dL and assessed severe hypoglycaemia and DKA. [131]A1a | Supplied abstract lacks pooled results. [131]A1a |
| Perioperative management | Open-source AID pilot excluded type 1 diabetes; transplantation case series used a six-phase institutional algorithm. [309][312]C | Limited generalisability and low-level evidence. [309][312]C |
| Adjunctive therapy | GLP-1 RA meta-analysis reported overall hypoglycaemia RR 1.01 and serious adverse events RR 0.89. [39]A1a | DKA estimate is not provided in the supplied abstract. [39]A1a |
| Medication-associated dysglycaemia | SGLT2i fracture meta-analysis and gamma-secretase inhibitor case report provide no emergency protocol. [310][311] | Acute-illness recommendations cannot be derived. [310][311] |
Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
- ▸Use CGM targets of **TIR 70–180 mg/dL >70%**, **CV <36%**, and **TBR <70 mg/dL <5%** as an evidence-supported multidimensional framework when clinically appropriate. [319]
- ▸Insulin replacement remains foundational; ultra-short-acting analogues, pump therapy, hybrid closed-loop systems, and once-weekly efsitora are evidence areas with differing maturity and incomplete comparative evidence in the supplied abstracts. [164][192][317][321][322]
- ▸GLP-1 receptor agonists, SGLT2 inhibitors, BCG, and stem-cell therapies should not replace insulin and remain adjunctive or investigational in T1DM based on the supplied evidence. [31][316][320]
- ▸SPKT can provide metabolic stabilization in selected patients with diabetes and ESRD, but perioperative evidence is limited to a small single-center case series. [312]
- ▸Sleep, circadian health, exercise safety, psychological burden, obesity, cardiovascular risk, and DKA prevention are integral to treat-to-target care. [315][162][135][275][286][300]
Treatment framework
Long-term management of type 1 diabetes mellitus (T1DM) remains centered on individualized insulin replacement, structured glucose monitoring, prevention of hypoglycemia and diabetic ketoacidosis (DKA), and reduction of cardiovascular and other diabetes-related risk. The supplied evidence supports treating to complementary glycemic targets rather than relying on HbA1c alone: one contemporary CGM study defined an “on-target” profile as time in range (70–180 mg/dL) >70%, coefficient of variation <36%, and time below range (<70 mg/dL) <5%. [319] These metrics should be interpreted with clinical context, treatment burden, hypoglycemia awareness, comorbidities, age, and patient priorities. [318][319]
Replacement: insulin and glucose-guided delivery
Insulin remains the essential replacement therapy for T1DM. Evidence synthesized in a 2026 Cochrane network meta-analysis evaluates ultra-short-acting and short-acting analogues against regular human insulin or other analogues in adults using multiple daily injections; the review’s purpose was to compare long-term glycemic and safety effects and rank these preparations, but the supplied abstract does not provide the comparative estimates. [164]A1a Once-weekly insulin efsitora is an emerging basal-insulin approach studied in randomized trials involving people with type 1 or type 2 diabetes; the systematic review assessed HbA1c and level 1, level 2, and level 3 hypoglycemia, but the supplied abstract does not establish that it should replace established basal insulin in T1DM. [192]A1a
Pump and automated insulin delivery can be selected when they improve the individual’s ability to meet glycemic targets, reduce treatment burden, or fit lifestyle. A nationwide U.S. inpatient analysis examined associations between pump use and 30-day readmission or in-hospital mortality among adults hospitalized with T1D, although the supplied abstract does not report the adjusted results and the observational design cannot establish causality. [317] Real-world data from 47 Chinese adults using a switchable tubeless/tubed two-in-one pump reported a mean HbA1c of 7.2 ± 1.4% before survey assessment; the study was descriptive, self-reported, and did not provide randomized comparative evidence. [321]C For adults initiating the MiniMed 780G advanced hybrid closed-loop system, virtual and in-person training were compared at 12 weeks; the study was retrospective and observational, so training modality should be individualized rather than presumed equivalent in every setting. [322]
Suppression: adjunctive and disease-modifying strategies
Adjunctive pharmacotherapy should not be considered a substitute for insulin replacement. A systematic review and meta-analysis of GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors included five T1DM studies within a broader evidence base and specifically evaluated lean body mass; the supplied abstract does not provide T1DM-specific effect estimates, so weight loss or body-composition benefits must not be assumed to outweigh safety concerns in T1DM. [31]A1a Pediatric evidence indicates a bidirectional relationship between obesity and T1DM, including associations with diabetes risk, post-diagnostic weight trajectories, and metabolic outcomes; weight management should therefore address nutrition, activity, insulin adequacy, and psychosocial factors without compromising insulin delivery. [135]B2a
BCG vaccination remains investigational as an adjunctive or disease-modifying intervention. A systematic review described supportive reports of improved C-peptide, lower HbA1c, partial β-cell recovery, and immune modulation, but also identified studies opposing benefit; this mixed evidence does not establish BCG as routine treatment. [320] Stem-cell therapy is likewise investigational: a meta-analysis identified eight reports from seven randomized trials involving 169 participants and evaluated HbA1c, fasting C-peptide, insulin-dose reduction, insulin independence, and adverse events, but the supplied abstract does not provide definitive efficacy estimates or support routine clinical use. [316]
Definitive or near-definitive approaches
Pancreas transplantation, including simultaneous pancreas-kidney transplantation (SPKT), is a definitive insulin-independent strategy considered in highly selected patients, particularly those with T1DM and end-stage renal disease. A 2026 case series described SPKT as an established treatment for selected patients with diabetes and ESRD and examined a six-phase intraoperative glycemic algorithm in 11 recipients; the small, single-center, retrospective design provides feasibility evidence rather than a generalizable treatment target. [312]C Perioperative glucose management should therefore be coordinated by transplant, endocrine, renal, and surgical teams. [312]C
Monitoring, safety, and supportive targets
CGM-based targets should be integrated with sleep and circadian assessment in adolescents. A systematic review specifically synthesized objectively measured sleep and circadian parameters and their associations with glycemic outcomes in adolescents aged 10–19 years, using PRISMA 2020 methods; the supplied abstract does not report pooled directional effects, but it supports considering sleep and circadian measures when glycemic control is difficult. [315] Exercise remains appropriate, but a randomized crossover trial in 12 adults found that perceived exertion was associated with cardiovascular strain and not with the acute glycemic response to gym-based aerobic or resistance exercise; perceived exertion therefore cannot replace glucose monitoring and individualized exercise precautions. [162]A1b
Psychological burden is a treatment target. In 101 adult users of the MyDiaMate application, commonly endorsed concerns included future complications, guilt or worry when diabetes was “out of control,” burnout, and feeling that diabetes controlled life; network modeling identified a densely interconnected burden domain. [318] Screening for distress, burnout, fear, and treatment fatigue should accompany technical intensification. [318]
Long-term cardiovascular prevention remains important because adult-onset T1DM was evaluated against propensity-matched T2DM for 10-year major adverse cardiovascular and cerebrovascular events in a U.S. TriNetX cohort; the study’s observational design and supplied abstract do not provide a treatment threshold, but it reinforces risk-stratified cardiovascular follow-up. [275]C Immune-checkpoint-inhibitor-associated T1DM is a distinct secondary form that may present with DKA; a systematic review and meta-analysis evaluated incidence, DKA occurrence, dual versus monotherapy exposure, pre-existing diabetes, and prognostic implications. [271] In contrast, a study of glargine for dexamethasone-induced hyperglycemia excluded people with T1DM, so its findings should not be extrapolated to routine T1DM management. [323]C
DKA prevention requires uninterrupted basal insulin, sick-day planning, ketone testing, and rapid escalation for vomiting or persistent hyperglycemia; recurrent DKA and poor adherence were described in a pediatric Mauriac-syndrome case, while another adolescent with DKA developed rhino-orbital-cerebral mucormycosis. [286]C[300]C Emphysematous pyelonephritis is a rare pediatric infection associated mainly with reflux or obstructive nephropathy rather than a routine T1DM target, but severe infection should prompt urgent assessment in a deteriorating child. [91]C4
Practical endpoint
The appropriate long-term endpoint is durable, individualized achievement of CGM glycemic targets with acceptable hypoglycemia, preserved quality of life, sustainable insulin use, and prevention of acute complications. [319][318] Replacement insulin and glucose-guided delivery are established pillars; adjunctive drugs, BCG, stem-cell approaches, novel weekly basal insulin, and transplantation require indication-specific specialist evaluation and should not be presented as interchangeable therapies. [31]A1a[164]A1a[192]A1a[312]C[316][320]
| Domain | Application | Evidence boundary |
|---|---|---|
| Glycemic target | TIR 70–180 mg/dL >70%; CV <36%; TBR <70 mg/dL <5% | Derived from a CGM-defined on-target phenotype, not a universal mandate. [319] |
| Replacement | Basal-bolus insulin, analogues, pumps, and automated delivery | Comparative and real-world evidence varies; observational studies do not prove causality. [164]A1a[317][321]C[322] |
| Suppression/adjuncts | GLP-1RA, SGLT2i, BCG, and stem-cell approaches | T1DM-specific efficacy, safety, or durability remains incompletely established in the supplied abstracts. [31]A1a[316][320] |
| Definitive therapy | Pancreas or SPKT transplantation in selected patients | Specialist indication; perioperative evidence includes a small retrospective case series. [312]C |
| Safety/support | DKA prevention, distress care, sleep, exercise, obesity, and cardiovascular surveillance | Requires individualized monitoring and multidisciplinary care. [315][162]A1b[135]B2a[275]C[318][286]C[300]C |
History and Evolution of Treatment
- ▸Modern T1DM treatment remains dependent on lifelong insulin replacement, with prevention of DKA and severe hypoglycaemia as core objectives. [220][84][286]
- ▸CSII and CGM have shifted assessment toward dynamic outcomes such as TIR; a pediatric crossover trial studied faster versus standard insulin aspart using TIR **3.9–10.0 mmol/L** as the primary endpoint. [324]
- ▸Severe hypoglycaemia prevention now includes risk prediction, neurodevelopmental protection, and individualized monitoring. [220][328]
- ▸Tele-nursing, exercise monitoring, microbiome interventions, and immunological biomarkers represent expanding adjunctive research areas rather than replacements for insulin. [331][162][186][259][326][333]
- ▸Family screening, autoantibody classification, genetic reassessment, and surveillance for autoimmune, neurologic, renal, dental, and vaccine-related issues increasingly form part of comprehensive care. [145][283][325][329][327][330][93][94][332]
From insulin replacement to individualized management
Treatment of type 1 diabetes mellitus (T1DM) is founded on lifelong insulin replacement because autoimmune β-cell destruction produces an absolute or near-absolute insulin deficiency. Contemporary management therefore aims not only to prevent symptomatic hyperglycaemia and diabetic ketoacidosis (DKA), but also to reduce hypoglycaemia, preserve quality of life, and limit long-term organ injury. [220]A1a The continuing clinical importance of reliable insulin delivery is illustrated by reports of recurrent DKA, hepatomegaly, growth-related Mauriac syndrome, and poor adherence in adolescents using mealtime insulin plus basal glargine. [286]C In adults, DKA remains a major cause of morbidity and mortality, particularly where access to diabetes education, monitoring, and emergency treatment is limited. [84]B2b
Intensive insulin therapy and glucose monitoring
The evolution from conventional insulin administration toward intensive regimens is reflected by the continuing use of multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII). MDI remains an important treatment platform, but severe hypoglycaemia can require emergency care; the SEHYPAN study developed predictive models specifically for adults with T1DM treated with MDI, emphasizing risk stratification as an element of modern insulin safety. [328] CSII combined with continuous glucose monitoring (CGM) permits more responsive adjustment of basal and prandial insulin. In a prospective randomized crossover trial of children and adolescents aged 6–17 years using CSII and CGM with HbA1c <8% (64 mmol/mol), faster insulin aspart was compared with standard insulin aspart using time in range (TIR; 3.9–10.0 mmol/L) as the principal outcome. [324] This design represents the shift from judging treatment primarily by HbA1c toward evaluating dynamic glucose exposure and TIR, although the supplied abstract does not provide the trial’s numerical between-treatment result. [324]
Hypoglycaemia prevention has become a central therapeutic objective because severe hypoglycaemia may affect neurodevelopment and cognition in children, especially when episodes occur during periods of brain development. [220]A1a Contemporary treatment selection therefore requires attention to age, symptom recognition, insulin sensitivity, monitoring access, and previous severe events. [220]A1a In adults treated with MDI, prediction models are being developed to identify those at highest risk of severe hypoglycaemia and to guide preventive intervention. [328]
Education, behavioral support, and telehealth
The therapeutic model has expanded beyond prescriptions to include structured education and sustained behavioral support. A randomized study of 67 adolescents aged 12–18 years evaluated six months of telephone-based tele-nursing after initial face-to-face education; the intervention targeted metabolic control, self-efficacy, quality of life, and anxiety in adolescents and their parents. [331] This reflects an evolution toward remotely supported self-management, particularly for young people who must independently coordinate insulin, food intake, glucose monitoring, and illness management. [331] Poor adherence, irregular meals, and inconsistent glucose monitoring remain clinically consequential, as demonstrated by the adolescent with recurrent DKA and Mauriac syndrome. [286]C
Exercise has likewise become part of individualized treatment rather than a generic recommendation. In an exploratory randomized crossover trial, adults with T1DM completed approximately 30-minute aerobic interval and resistance-training sessions; perceived exertion was associated with cardiovascular strain but not with the acute glycaemic response. [162]A1b Consequently, perceived exertion may help monitor cardiovascular effort in gym settings, but it cannot substitute for glucose monitoring or individualized insulin-and-carbohydrate planning when preventing exercise-related dysglycaemia. [162]A1b
Adjunctive and emerging approaches
Recent research is testing adjunctive interventions that do not replace insulin. A double-blind pilot trial assigned 68 children aged 8–18 years with established T1DM to 12 weeks of 8 g/day oligofructose-enriched inulin or isocaloric maltodextrin placebo, assessing HbA1c and stool microbiome profiles. [186]A1b This approach arises from evidence of gut microbial dysbiosis and interest in short-chain-fatty-acid-producing bacteria, but the pilot nature of the study limits conclusions about routine treatment. [186]A1b The gut–brain axis is also being investigated as a possible link between obesity and T1DM; proposed next steps include mechanistic studies, gnotobiotic models, targeted metabolomics, and research designed to distinguish causation from correlation. [259]
Immunological and disease-modifying strategies remain investigational. Studies associating dendritic-cell ADAM19 expression with immune features and lower C-peptide levels, and examining interleukin-6 and oncostatin M in relation to glycaemic indices, support continued exploration of immune pathways and residual β-cell function but do not establish a clinical treatment. [326][333] Similarly, thyroid autoimmunity at diagnosis and its relationship to islet autoantibodies reinforces the need to identify associated autoimmune disease during initial evaluation and follow-up rather than altering insulin replacement on the basis of antibodies alone. [329]
Risk stratification, screening, and comprehensive care
Treatment evolution increasingly incorporates earlier risk identification. In children with T1DM, autoantibody-positive and autoantibody-negative presentations may differ clinically and biochemically, making classification important when considering atypical diabetes and follow-up. [283] Screening first-degree relatives for ZnT8A, GADA, IAA, and IA-2A has been studied in Turkish children aged 2–18 years, alongside assessment of anxiety after result disclosure, illustrating the need to combine preventive screening with psychological support. [145]C4 Familial occurrence was also evaluated in a multicentre Korean pediatric cohort, demonstrating the relevance of family history in contemporary case finding and counseling. [325]
Modern care additionally addresses complications and comorbid risks. Cognitive and brain-volume changes have been studied in young adults with long-standing T1DM, while oral sensory neuropathy may present with either hyperaesthesia or hypoaesthesia and affect dental safety. [327][330]C Reduced hepatitis B antibody responses in children with T1DM have prompted consideration of revaccination protocols. [332] Renal presentations may be multifactorial: a case of proliferative glomerulonephritis with monoclonal IgG1-κ deposits occurred after 19 years of poorly controlled T1DM, underscoring the need to investigate atypical proteinuria rather than attributing every renal abnormality to diabetic nephropathy. [93]C4 Finally, transient GADA positivity and a pathogenic GCK variant in a child with severe insulin resistance demonstrate why atypical cases require genetic and clinical reassessment before committing to a T1DM treatment pathway. [94]C4
| Treatment direction | Current evidence and clinical implication |
|---|---|
| Insulin replacement | Lifelong insulin remains fundamental; poor adherence increases DKA and complication risk. [220]A1a[84]B2b[286]C |
| MDI safety | Severe-hypoglycaemia prediction models are being developed for adults using MDI. [328] |
| CSII and CGM | Pediatric studies evaluate rapid-acting analogues using TIR 3.9–10.0 mmol/L rather than HbA1c alone. [324] |
| Education and telehealth | Telephone-based follow-up after face-to-face education targets metabolic control and psychosocial outcomes. [331] |
| Exercise integration | Perceived exertion reflects cardiovascular strain but does not reliably predict glycaemic response. [162]A1b |
| Adjunctive research | Prebiotics, gut–brain mechanisms, and immune biomarkers remain investigational. [186]A1b[259][326][333] |
| Precision and prevention | Autoantibody, family-history, genetic, and comorbidity assessment increasingly guide individualized care. [145]C4[283][325][329][94]C4 |
Multiglandular Syndromes, Genetic Context and Co-Axis Effects
- ▸Screen for autoimmune thyroid disease and celiac disease in T1DM; additional autoimmune disease may be under-recognized after an initial associated diagnosis. [336]
- ▸For preconception care, use HbA1c <6.5% when safely achievable and CGM glucose 3.9–10.0 mmol/L for at least 70% of time. [217]
- ▸Interpret thyroid tests during DKA cautiously because euthyroid sick syndrome may recover after DKA resolution; reassessment at 2 weeks was used in pediatric evidence. [92]
- ▸Autoantibody-negative pediatric diabetes should prompt consideration of monogenic or syndromic diabetes when the phenotype is atypical. [283]
- ▸Severe insulin resistance, immune dysregulation, and recurrent DKA may indicate a broader genetic or syndromic context rather than isolated autoimmune T1DM. [47][335][286]
Autoimmune clustering and polyglandular syndromes
Type 1 diabetes mellitus (T1DM) commonly coexists with autoimmune thyroid disease (AITD) and celiac disease (CeD), forming an autoimmune-polyglandular phenotype that requires surveillance beyond glycemia. [336] In a 2026 cross-sectional study, adults with T1DM and AITD and/or CeD underwent an extended autoimmune work-up because guidance on additional screening after an initial associated autoimmune diagnosis remains limited; the study specifically addressed under-recognition of further autoimmune conditions. [336] Autoimmune thyroid disease may comprise Hashimoto thyroiditis or Graves disease, and their coexistence with T1DM is classified as autoimmune polyglandular syndrome type 3 (APS3). [338]
The practical core of screening is thyroid and celiac assessment. [336] In women with T1DM planning pregnancy, thyroid-stimulating hormone measurement is specifically included in preconception assessment, alongside evaluation of microangiopathic and macroangiopathic complications and cardiovascular risk factors. [217]A1c The French expert consensus recommends preconception HbA1c <6.5% when achievable without problematic hypoglycemia and, for users of continuous glucose monitoring, glucose of 3.9–10.0 mmol/L (70–180 mg/dL) for at least 70% of the time. [217]A1c These targets are pregnancy-planning standards rather than diagnostic criteria for APS.
Thyroid co-axis effects
Thyroid dysfunction can alter insulin requirements, metabolism, and interpretation of nonspecific symptoms in T1DM; however, the supplied evidence does not quantify these effects directly. [217]A1c Acute illness can also transiently suppress thyroid hormones without primary thyroid disease. In 182 children with T1DM admitted for diabetic ketoacidosis (DKA), euthyroid sick syndrome was evaluated at presentation and again 2 weeks after DKA resolution, using age-specific TSH, free thyroxine, and free triiodothyronine reference ranges. [92]B2b Thyroid testing obtained during DKA should therefore be interpreted in clinical context and, when appropriate, reassessed after recovery rather than automatically labeling the result as chronic AITD. [92]B2b
SIGLEC1, an interferon-inducible molecule, was investigated as a potential immune marker across AITD, T1DM, and APS3. [338] The study included 219 patients, with 213 available for the primary molecular analysis: AITD alone (n=127), T1DM alone (n=59), and APS3 (n=27); SIGLEC1 mRNA levels differed significantly among the groups. [338] These findings support immunologic heterogeneity across autoimmune phenotypes but do not establish SIGLEC1 as a validated diagnostic or screening test. [338]
Gastrointestinal and renal co-axis effects
CeD is clinically important because gastrointestinal symptoms, malabsorption, low body mass index, and short stature may overlap with or aggravate diabetes-related nutritional problems. [226]A1a A 2025 systematic review and meta-analysis examined CeD prevalence in high-risk populations in China, including people with autoimmune disease, gastrointestinal symptoms, low body mass index, and short stature; the supplied abstract does not provide the pooled T1DM-specific estimate. [226]A1a Accordingly, the reference supports risk-based consideration of CeD but not a population-specific prevalence threshold. [226]A1a
Polyuria in a child with T1DM is not synonymous with uncomplicated hyperglycemia. A systematic review identified 32 pediatric acute kidney injury (AKI) cases, including 19 with DKA, 5 with new-onset T1DM without DKA, 1 with Bartter syndrome, and 1 with neuroblastoma; 26 children presented with polyuria. [41]C4 Volume depletion, DKA, and alternative renal or endocrine diagnoses should therefore be considered when polyuria is severe, persistent, or accompanied by kidney dysfunction. [41]C4
Genetic and nonautoimmune diabetes context
Most childhood T1DM is autoimmune, but autoantibody-negative presentations require diagnostic caution. In a Dutch pediatric cohort of 562 patients, 1.4% were reported as having a monogenic diabetes diagnosis among the autoantibody-negative group in the supplied abstract; the study compared autoantibody-positive and autoantibody-negative clinical and biochemical characteristics. [283] Negative islet autoantibodies do not by themselves prove monogenic diabetes, but atypical phenotype, family history, preserved endogenous insulin secretion, or syndromic features should prompt consideration of genetic diabetes. [283]
Primary immune dysregulation can produce diabetes-like or multisystem autoimmune phenotypes. LRBA deficiency is a primary immunodeficiency associated with immune dysregulation, autoimmunity, and lymphoproliferation; a five-family Moroccan case series demonstrated marked heterogeneity, ranging from isolated immune thrombocytopenia to severe multisystem disease. [47]C4 Such syndromic findings warrant immunology and genetic evaluation rather than assuming isolated T1DM. [47]C4 Severe insulin resistance may also coexist with a T1DM diagnosis: a pediatric case series described four patients with Rabson–Mendenhall syndrome, one with insulin-receptor type 1A disease, and one with T1DM plus severe subcutaneous insulin resistance; all reportedly responded substantially to dapagliflozin, but the evidence was limited to six cases and does not establish routine use. [335]C
Metabolic co-axes and treatment effects
Insulin resistance can contribute to poor metabolic outcomes and microvascular complications in T1DM. [308] In a 263-adult Iraqi cross-sectional study, estimated glucose disposal rate (eGDR) was used as a validated surrogate of insulin resistance and was assessed against microvascular complications and metabolic syndrome; observational associations do not establish causality or a universal treatment threshold. [308]
Weight-loss pharmacotherapies may change body composition in T1DM. A systematic review and meta-analysis identified 36 randomized trials across obesity, type 2 diabetes, T1DM, and polycystic ovary syndrome, including five T1DM studies, and evaluated lean body mass (LBM) with GLP-1 receptor agonists or SGLT2 inhibitors. [31]A1a The supplied abstract does not report the T1DM-specific pooled LBM estimate; therefore, these agents should not be presumed to preserve lean mass in T1DM. [31]A1a SGLT2 inhibitor use also requires particular caution because DKA risk is clinically relevant, while pediatric evidence for dapagliflozin in severe insulin resistance remains case-based. [335]C
Other syndromic and reproductive contexts
Poor insulin adherence and recurrent DKA can produce Mauriac syndrome, characterized in a reported 14-year-old with longstanding T1DM by irregular meals, inconsistent monitoring, recurrent DKA, hepatomegaly, and growth-related complications; this is a case-report signal rather than a prevalence estimate. [286]C Maternal autoimmune disease is associated with adverse pregnancy outcomes in a UK cohort of approximately five million pregnancies, although the supplied abstract does not provide T1DM-specific effect estimates. [83]B2b Prenatal exposure to maternal autoimmune or autoinflammatory disorders was also associated at modest effect sizes with several primarily early-onset neurodevelopmental disorders in offspring, but this evidence is not specific to maternal T1DM. [165]B2b PCOS is heterogeneous and may coexist with autoimmune thyroiditis and other autoimmune diseases; a retrospective study of 1,249 women aged 18–44 years examined these relationships, but it does not establish a causal link with T1DM. [278] Associations between T1DM and postoperative complications after hip arthroscopy, outcomes after simultaneous pancreas–kidney transplantation, childhood leukemia, oral manifestations, or acute hepatic porphyria are context-specific findings and should not be interpreted as defining multiglandular T1DM syndromes. [312]C[313][314][334]C[337]C
| Co-axis or context | Evidence-supported implication |
|---|---|
| Thyroid | Screen in T1DM; interpret thyroid tests during DKA cautiously and reassess after recovery when indicated. [217]A1c[92]B2b |
| Celiac disease | Consider with gastrointestinal symptoms, low BMI, short stature, or other autoimmune disease; the supplied evidence does not provide a T1DM-specific Chinese prevalence estimate. [226]A1a |
| Genetic diabetes | Consider monogenic disease in autoantibody-negative or atypical pediatric diabetes. [283] |
| Immune dysregulation | LRBA deficiency can cause multisystem autoimmunity and lymphoproliferation. [47]C4 |
| Insulin resistance | eGDR is an observational surrogate; severe resistance may reflect insulin-receptor disorders or unusual subcutaneous resistance. [308][335]C |
| Pregnancy | Preconception glycemic, thyroid, renal, vascular, and complication assessment is required. [217]A1c |
Complications and Long-term Sequelae
- ▸DKA remains a critical acute complication; intentional insulin omission is associated with DKA, microvascular complications, and increased mortality. [74]
- ▸CVD is a major long-term complication, with lifestyle factors, dyslipidemia, platelet-inflammatory markers, and exercise-related cardiovascular strain relevant to risk assessment. [162][234][236][275][340][342]
- ▸T1D is associated with renal disease, osteoporosis risk, microvascular complications, and additional autoimmune diseases. [233][274][312][341][343]
- ▸Psychological burden is common, particularly worry about future complications, diabetes burnout, guilt, and perceived loss of control. [318]
- ▸CGM and automated insulin delivery may improve management, but evidence remains limited in complex settings such as dialysis and does not eliminate the need for complication surveillance. [343][344]
Overview
Type 1 diabetes mellitus (T1D) produces complications through persistent glycemic disturbance, vascular risk, autoimmune comorbidity, treatment-related hazards, and psychosocial burden. The updated evidence base includes systematic reviews, cohort and case-control studies, clinical trials, mechanistic analyses, case reports, and animal research; therefore, associations should not automatically be interpreted as causal or universally applicable. [339][162]A1b[271][74]D5[340][341][261][233]B3b[318]
Acute metabolic and infectious complications
Diabetic ketoacidosis (DKA) remains a major acute complication of T1D and may be precipitated by inadequate insulin administration. Intentional insulin omission—often termed “diabulimia”—is mainly described in adolescents and young adults, is linked to eating-disorder psychopathology, and carries risks of DKA, microvascular complications, and increased mortality. [74]D5 Insulin omission is also clinically relevant in hospitalized adults: a 2022 U.S. Nationwide Readmissions Database analysis evaluated 30-day readmission and in-hospital mortality according to insulin-delivery modality, reflecting substantial inpatient morbidity in adults with T1D. [317]
DKA can be complicated by invasive infection. A 2026 case report described rhino-orbital-cerebral mucormycosis after DKA in a 14-year-old with T1D; the infection is rapidly progressive and associated with substantial mortality and disability, while early symptoms may be insidious and diagnosis delayed. [300]C In a murine spinal-implant model, both streptozotocin-induced T1D and diet-induced type 2 diabetes were investigated for infectious burden, wound healing, inflammatory responses, and response to semaglutide; these findings are preclinical and should not be used to establish human treatment recommendations for T1D. [261]
Cardiovascular and cerebrovascular disease
Cardiovascular disease (CVD) remains a major long-term complication of T1D. [340] In a prospective UK Biobank cohort of participants with T1D free of CVD at baseline, investigators examined incident CVD in relation to six lifestyle factors: smoking, alcohol consumption, body mass index, diet quality, physical activity, and sleep duration. [340] This supports assessment of lifestyle as part of cardiovascular risk management, although the cited abstract does not provide the effect estimates needed to quantify risk reduction. [340]
Adult-onset T1D was compared with type 2 diabetes in a propensity-matched U.S. TriNetX cohort followed through 2025, with 10-year major adverse cardiovascular and cerebrovascular event risk evaluated across age, HbA1c, and non-insulin antihyperglycemic-use strata. [275]C Dyslipidemia is an important modifiable cardiovascular risk factor in youth with T1D; an Australian pediatric audit found incomplete adherence to initial lipid-screening guidance and testing intervals longer than recommended in routine care. [234]C4 A 2026 meta-analysis specifically assessed whether omega-3 polyunsaturated-fatty-acid supplementation alters total, LDL, and HDL cholesterol, triglycerides, fasting plasma glucose, and HbA1c in T1D; the available abstract does not report the pooled direction or magnitude of effects. [339]
Platelet indices, adiponectin, leptin, and C-reactive protein were examined in adults with long-standing T1D because chronic inflammation, platelet-related changes, and cardiovascular risk may be interrelated. [342] In adolescents with T1D, the triglyceride-glucose index and bioelectrical-impedance phase angle were investigated as potential markers of glycemic control, body composition, and cardiovascular risk; their clinical utility remains investigational because the study was cross-sectional. [236]C4 Exercise is generally important for cardiovascular risk mitigation, but an exploratory randomized crossover trial found that perceived exertion was associated with cardiovascular strain rather than the acute glycemic response during approximately 30-minute aerobic or resistance sessions in 12 adults with T1D. [162]A1b
Microvascular, renal, sleep-related, and skeletal sequelae
High-risk obstructive sleep apnea (OSA) was assessed in 102 adults with T1D and 126 controls using the modified Berlin Questionnaire, with analysis of its relationship to microvascular complications. [233]B3b Because this was a case-control study using questionnaire-based OSA risk assessment, it establishes clinical association rather than causation. [233]B3b
T1D is also associated with clinically important renal disease. A case report described automated insulin delivery in a woman with T1D, visual impairment, multiple diabetes-associated complications, and end-stage kidney disease requiring peritoneal dialysis; the report suggests feasibility in a complex individual but cannot establish safety or efficacy for the broader dialysis population. [343]C Simultaneous pancreas-kidney transplantation remains an established treatment option for selected patients with diabetes and end-stage renal disease; a single-center series of 11 patients examined phase-specific intraoperative glycemic management, highlighting the importance of perioperative glucose control for graft viability. [312]C
Genetic causal-inference analysis using two-sample Mendelian randomization investigated the relationship between T1D and osteoporosis and examined BMI, HbA1c, medium very-low-density-lipoprotein cholesterol, saturated fatty acids, and sex hormone-binding globulin as possible mediators. [341] These results strengthen investigation of bone fragility in T1D but do not replace fracture-risk assessment or prove that modifying each mediator prevents osteoporosis. [341]
Autoimmune and psychosocial complications
Children and adolescents with T1D have increased risk of additional autoimmune diseases. A retrospective cohort of 639 pediatric patients evaluated their frequency, spectrum, timing, clinical characteristics, and associated autoantibody findings. [274] Screening should therefore remain attentive to autoimmune comorbidity, while recognizing that the study was conducted at a tertiary center and may not represent all populations. [274]
Psychological burden is itself a long-term sequela with potential consequences for self-management. In Polish MyDiaMate data from 101 adults, the most frequently endorsed concerns involved future complications (85.1%), guilt or worry when diabetes was out of control (79.2%), diabetes burnout (72.3%), and feeling that diabetes controlled one’s life (72.3%). [318] Network modeling identified a densely interconnected psychological-burden domain, suggesting that interventions may need to address burnout, distress, guilt, and perceived loss of control together rather than in isolation. [318] The gut-brain axis and obesity in T1D remain emerging areas; proposed research priorities include mechanistic studies, gnotobiotic models, and targeted metabolomics to distinguish correlation from causation and evaluate therapeutic applications. [259]
Technology and prevention
Continuous glucose monitoring (CGM) is reviewed as a technology with potential effects on clinical outcomes and diabetes-management costs, while limitations differ across major commercial platforms, including Dexcom, Medtronic, and FreeStyle systems. [344] Automated insulin delivery is described as the treatment standard in the cited case report and may be promising in T1D with peritoneal dialysis, although evidence in this setting remains limited. [343]C Overall, prevention of long-term sequelae requires individualized glycemic monitoring, cardiovascular-risk assessment, complication screening, psychological support, and rapid recognition of DKA and severe infection. [74]D5[233]B3b[234]C4[317][318][344]
| Domain | Updated evidence |
|---|---|
| Acute metabolic/infectious | Insulin omission is linked to DKA and mortality; DKA-associated rhino-orbital-cerebral mucormycosis has been reported. [74]D5[300]C |
| Cardiovascular | Cohort and matched-comparator studies assess incident CVD and 10-year major adverse cardiovascular and cerebrovascular events. [275]C[340] |
| Microvascular/renal | High-risk OSA was examined in relation to microvascular complications; complex renal disease may require dialysis or transplantation. [233]B3b[312]C[343]C |
| Skeletal/autoimmune | Mendelian-randomization work evaluates T1D–osteoporosis pathways, while pediatric cohorts document additional autoimmune disease. [274][341] |
| Psychosocial/technology | Diabetes distress and burnout are prominent; CGM and automated insulin delivery are important management technologies. [318][343]C[344] |
Prognosis, Natural History, Special Populations and Prevention
- ▸Long-term T1DM prognosis is influenced by cardiovascular, retinal, renal, glycemic, psychosocial, and autoimmune complications. [275][82][295][281][274]
- ▸CGM is a major management advance, but the supplied evidence does not establish one universally superior platform. [344]
- ▸Hospital hypoglycemia in newly diagnosed youth is defined in the cited study as glucose <3.9 mmol/L; grade 2 is <3.0 mmol/L. [348]
- ▸A DEPS-R score ≥20 is the cited threshold for positive screening for disordered eating behaviors. [281]
- ▸BCG vaccination, vitamin supplementation, and seasonal or autoantibody-based approaches remain investigational or risk-stratification strategies rather than proven population prevention. [320][347][346][145]
Overall prognosis and natural history
Type 1 diabetes mellitus (T1DM) is a lifelong disorder requiring exogenous insulin, and its long-term prognosis is shaped by glycemic exposure, cardiovascular risk, microvascular complications, psychosocial factors, and access to diabetes technology. Contemporary evidence in the supplied literature is heterogeneous, consisting of systematic reviews, retrospective cohorts, cross-sectional studies, case series, and single-center reports; therefore, most findings should be interpreted as associations rather than causal or universally generalizable estimates. [344][275]C[82]B3b
In a U.S. propensity-matched database study of adults with adult-onset T1DM diagnosed during 2005–2015 and followed through 2025, investigators compared 10-year major adverse cardiovascular and cerebrovascular event (MACCE) risk with that of adults with T2DM after matching on demographic and clinical covariates. The study specifically examined stroke, hemorrhage, cardiac arrest, heart failure, myocardial infarction, and peripheral vascular events, with additional stratification by age, HbA1c, and non-insulin antihyperglycemic use; the supplied abstract does not report the numerical risk estimates. [275]C These findings emphasize that adult-onset T1DM carries clinically important long-term cardiovascular considerations, although the available abstract does not permit quantitative prognostic conclusions. [275]C
Microvascular disease remains a major determinant of preventable morbidity. In a retrospective Riyadh cohort of 449 patients with T1DM aged ≥9 years, followed from 2015 to 2025, diabetic retinopathy incidence and clinical predictors were evaluated; the supplied abstract identifies retinopathy as an important cause of preventable visual impairment but does not provide the cohort’s numerical incidence or adjusted predictors. [82]B3b Diabetic kidney disease is likewise an important complication. A pediatric case-control study compared 30 children with T1DM and kidney disease, 30 with T1DM without kidney disease, and 30 controls to assess urinary fatty acid-binding protein 1 (FABP1), a proximal-tubular injury biomarker; the study describes albuminuria as the current diagnostic and staging standard while evaluating whether FABP1 may detect earlier tubular involvement. [295]
Glycemic management and complications
Continuous glucose monitoring (CGM) is presented in the supplied review as a major development in diabetes management, with potential effects on glycemic outcomes, clinical care, costs, and treatment limitations across commercial platforms; the review does not establish a single universally superior system or provide a specific outcome estimate in the supplied abstract. [344] Newly diagnosed children may experience hypoglycemia during hospitalization. A Chinese retrospective study included 567 patients aged <18 years and classified hypoglycemia as glucose <3.9 mmol/L, with grade 1 defined as 3.0–3.9 mmol/L and grade 2 as <3.0 mmol/L; logistic regression was used to identify associated factors, but the supplied abstract does not report the final incidence or predictors. [348]
Youth dyslipidemia is an emerging modifiable cardiovascular risk factor. In an Australian pediatric audit of 335 patients with T1DM, 78% followed initial lipid-screening guidance, while the mean interval between tests was 17 months rather than the recommended 5 years; the supplied abstract does not report subsequent treatment outcomes or lipid-event rates. [234]C4 These data support systematic cardiovascular risk surveillance, while recognizing that screening adherence and guideline implementation may vary by setting. [234]C4
Disordered eating behaviors (DEBs) are an important psychosocial complication. The Spain-D1ANAS cross-sectional study enrolled 451 people aged ≥16 years with T1DM and used the Diabetes Eating Problems Survey-Revised; a score of ≥20 constituted a positive screen. [281] Because the study was cross-sectional and questionnaire-based, it estimates screening positivity and associated factors rather than establishing temporal causation or long-term prognosis. [281]
Special populations and comorbidity
Children and adolescents with T1DM may develop additional autoimmune disease. A retrospective tertiary-center cohort included 639 pediatric patients followed from 2004 to 2018 and evaluated the frequency, spectrum, timing, and associated factors of autoimmune comorbidities. [274] Related pediatric celiac-disease research describes celiac disease as frequently coexisting with other immune-mediated conditions, although its single-center Romanian cohort consisted of children with celiac disease rather than a general T1DM population. [299]C GAD65 antibodies may also occur in T1DM and autoimmune thyroid disease and, less commonly, in pediatric autoimmune encephalitis; a three-patient pediatric case series illustrates neurologic presentations but cannot estimate population risk. [349]
Obesity and T1DM may have a bidirectional relationship in children and adolescents. A systematic review of studies published from 2010 through January 2026 evaluated obesity-related T1DM risk, post-diagnostic weight trajectories, and metabolic outcomes, but the supplied abstract does not provide a pooled effect estimate. [135]B2a Vitamin A and vitamin D status were examined in a small retrospective study of 31 children with T1DM and 31 controls; its observational design and sample size do not establish that supplementation prevents T1DM. [347]
In patients receiving immune checkpoint inhibitors, ICI-induced T1DM is a rare but potentially life-threatening endocrine immune-related adverse event. A 2026 systematic review and meta-analysis evaluated incidence, DKA occurrence, risk factors, and prognostic implications, including dual versus monotherapy exposure and pre-existing diabetes; the supplied abstract does not report pooled numerical estimates. [271]
Prevention and emerging strategies
No preventive intervention is established by the supplied evidence. A systematic review of BCG vaccination evaluated prevention and adjunctive treatment through immunomodulatory and metabolic mechanisms. Supportive studies reported improved C-peptide, lower HbA1c, partial β-cell recovery, and TNF-related immune modulation, but other studies opposed or failed to support these effects; BCG should therefore be regarded as investigational rather than routine prevention or treatment. [320] Autoantibody screening may identify risk in relatives: a Turkish multicenter study screened 440 first-degree relatives aged 2–18 years for ZnT8A, GADA, IAA, and IA-2A and also assessed anxiety after disclosure, but the supplied abstract does not provide prevalence estimates or clinical outcomes. [145]C4 A 40-year cohort of 2,954 patients diagnosed from 1981–2024 found age- and immunity-dependent seasonal patterns, with no seasonal fluctuation in early-onset T1DM; this supports biological heterogeneity rather than a proven seasonal prevention strategy. [346]
Related evidence with limited direct applicability
The pediatric emphysematous-pyelonephritis review identified reflux or obstructive nephropathy as the major risk factor in 52.3% of cases, but it is not a T1DM prognosis study. [91]C4 A case report of proliferative glomerulonephritis with monoclonal IgG1-κ deposits occurred after 19 years of T1DM with poor glycemic control, but this rare renal disorder cannot be considered a typical diabetic complication. [93]C4 A single-center case series of 11 patients undergoing simultaneous pancreas-kidney transplantation examined a six-phase intraoperative glycemic algorithm; it supports feasibility assessment only and does not establish long-term graft or survival benefit. [312]C Asian Global Burden of Disease 2021 analyses described diabetes and subtype-specific trends and attributable risks from 1990–2021, but the supplied abstract does not provide T1DM-specific numerical estimates. [345]
| Domain | Evidence and interpretation |
|---|---|
| Cardiovascular risk | Adult-onset T1DM versus propensity-matched T2DM was assessed for 10-year MACCE risk; numerical estimates are not available in the supplied abstract. [275]C |
| Retinopathy | A Riyadh cohort of 449 patients aged ≥9 years evaluated incidence and predictors through 2025; numerical results are not available in the supplied abstract. [82]B3b |
| Hypoglycemia | In newly diagnosed hospitalized youth, hypoglycemia was <3.9 mmol/L; grade 1 was 3.0–3.9 mmol/L and grade 2 was <3.0 mmol/L. [348] |
| Psychosocial risk | In 451 Spanish participants aged ≥16 years, DEPS-R ≥20 defined a positive DEB screen. [281] |
| Prevention | BCG showed mixed clinical and mechanistic evidence and remains investigational. [320] |
| Risk screening | Turkish screening included 440 first-degree relatives aged 2–18 years and measured ZnT8A, GADA, IAA, and IA-2A. [145]C4 |
References
- [1]
Dost A, Bechtold S, Fink K et al.. “2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents With Type 1 Diabetes.” Diabetes care (2020). PMID: 32229598 ↗
L2GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [2]
de Vries M, Westerink J, Kaasjager KHAH et al.. “Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827432 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [3]
Wada E, Onoue T, Kinoshita T et al.. “Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study.” Diabetologia (2021). PMID: 34268631 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation - [4]
Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [5]
Amato MC, Guarnotta V, Ciresi A et al.. “No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24243639 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [6]
Codner E, Soto N, Lopez P et al.. “Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16569737 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [7]
Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [8]
Marques-Couto P, Afonso J, Coelho-Costa I et al.. “Prevalence and Risk Factors of Diabetic Macular Edema in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Ophthalmology. Retina (2025). PMID: 41016555 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature - [9]
Weissmann S, Amitai N, Honig E et al.. “Maternal type 1 diabetes mellitus and atopic dermatitis in offspring: A nationwide cohort study.” JAAD international (2026). PMID: 42100114 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [10]
Kim KJ, Kim S, Oh R et al.. “High Waist-to-Height Ratio Increases the Risk of Cardiovascular Outcomes in Adults with Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2025). PMID: 40904015 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [11]
Weng SS, Chien LY. “IVF and risk of Type 1 diabetes mellitus: a population-based nested case-control study.” Human reproduction (Oxford, England) (2024). PMID: 38852062 ↗
L3CASE_CONTROLCited in: Definition, Classification and Axis Nomenclature - [12]
Tetik Dinçer B, Urgancı N, Koç A et al.. “Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease: a retrospective cohort study.” BMC pediatrics (2025). PMID: 41430660 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [13]
Zan Y, Wei Y, Zhang W et al.. “Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review.” Medicine (2025). PMID: 40388765 ↗
L4SR_OBSCited in: Definition, Classification and Axis Nomenclature - [14]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [15]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [16]
Pozzilli P, Bosi E, Cirkel D et al.. “Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32219329 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment - [17]
Pescovitz MD, Greenbaum CJ, Bundy B et al.. “B-lymphocyte depletion with rituximab and β-cell function: two-year results.” Diabetes care (2013). PMID: 24026563 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [18]
Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [19]
Du M, Basu A, Fu D et al.. “Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study.” Diabetes care (2013). PMID: 23393212 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [20]
de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [21]
Geddes J, Deary IJ, Frier BM. “Effects of acute insulin-induced hypoglycaemia on psychomotor function: people with type 1 diabetes are less affected than non-diabetic adults.” Diabetologia (2008). PMID: 18709352 ↗
L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [22]
Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [23]
Morkos M, Nensey NK, Bindal A. “Micafungin-Induced Hypoglycemia in a Patient With Type 1 Diabetes: A Case Report and Review of Literature.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398618 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [24]
Yoneda S, Imagawa A, Fukui K et al.. “A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28398495 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [25]
Fazeli PK, Horowitz MC, MacDougald OA et al.. “Marrow fat and bone--new perspectives.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23393168 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [26]
Tomar N, Gupta N, Goswami R. “Calcium-sensing receptor autoantibodies and idiopathic hypoparathyroidism.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23873991 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [27]
Hough FS, Pierroz DD, Cooper C et al.. “MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus.” European journal of endocrinology (2015). PMID: 26537861 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [28]
Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [29]
Kratzsch J, Knerr I, Galler A et al.. “Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor.” European journal of endocrinology (2006). PMID: 16990661 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [30]
Assmann TS, Brondani Lde A, Bauer AC et al.. “Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24408902 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [31]
Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [32]
Frandsen CS, Dejgaard TF, Madsbad S. “Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.” The lancet. Diabetes & endocrinology (2016). PMID: 26969516 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [33]
Elliott J, Sloan G, Stevens L et al.. “Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study.” Diabetologia (2023). PMID: 37870649 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [34]
Korczak DJ, Pereira S, Koulajian K et al.. “Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link.” Diabetologia (2011). PMID: 21789690 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification - [35]
Pane JA, Coulson BS. “Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes.” Diabetologia (2015). PMID: 25794781 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [36]
Roca-Rivada A, Marín-Cañas S, Colli ML et al.. “Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.” Diabetologia (2023). PMID: 36988639 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [37]
Nieuwdorp M, Holleman F, de Groot E et al.. “Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis.” Diabetologia (2007). PMID: 17415544 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae - [38]
Segev Y, Eshet R, Yakir O et al.. “Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.” Diabetologia (2007). PMID: 17443310 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [39]
Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [40]
Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [41]
Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [42]
Jawad M, Afaq S, Hussain S et al.. “Effect of digital interventions on adherence to the management of type 1 diabetes mellitus patients: a systematic review.” BMC endocrine disorders (2025). PMID: 41462455 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [43]
Chen Y, Tang Y, Yue R et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41331723 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [44]
Biondi B, Kahaly GJ, Robertson RP. “Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.” Endocrine reviews (2019). PMID: 30649221 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [45]
Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [46]
Rotondi M, Chiovato L, Romagnani S et al.. “Role of chemokines in endocrine autoimmune diseases.” Endocrine reviews (2007). PMID: 17475924 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [47]
Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [48]
Al Hayek A, Robert AA, Al Burayk AK et al.. “Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.” Current diabetes reviews (2026). PMID: 41691684 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [49]
Horton WB, Snell-Bergeon JK. “Hemoglobin A1c Variability Metrics Predict Coronary Artery Calcium and Cardiovascular Events in Type 1 Diabetes: The CACTI Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637994 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [50]
Tsaitlin-Mor L, Cahen-Peretz A, Bentov Y et al.. “Long-term Risk for Type 1 Diabetes and Obesity in Early Term Born Offspring: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38079466 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [51]
Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [52]
Nicholson WK, Robinson KA, Smallridge RC et al.. “Prevalence of postpartum thyroid dysfunction: a quantitative review.” Thyroid : official journal of the American Thyroid Association (2006). PMID: 16839259 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [53]
Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [54]
Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [55]
Drenthen LCA, Ajie M, Abbink EJ et al.. “No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study.” Diabetologia (2023). PMID: 36879098 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [56]
Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [57]
Morgan E, Halliday SR, Campbell GR et al.. “Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2015). PMID: 26564178 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [58]
de Vries SAG, Verheugt CL, Mul D et al.. “Do sex differences in paediatric type 1 diabetes care exist? A systematic review.” Diabetologia (2023). PMID: 36700969 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [59]
Jeitler K, Horvath K, Berghold A et al.. “Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.” Diabetologia (2008). PMID: 18351320 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [60]
Cardwell CR, Stene LC, Joner G et al.. “Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2008). PMID: 18292986 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [61]
Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [62]
Chou IC, Wang CH, Lin WD et al.. “Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study.” Diabetologia (2016). PMID: 27030312 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [63]
Dafoulas GE, Toulis KA, Mccorry D et al.. “Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study.” Diabetologia (2016). PMID: 27796422 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [64]
Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [65]
Li FR, Hukportie DN, Yang J et al.. “Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes.” Diabetes care (2022). PMID: 35944243 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [66]
Chen X, Affinati AH, Lee Y et al.. “Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.” Diabetes care (2022). PMID: 35238899 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [67]
Jacobson AM, Braffett BH, Erus G et al.. “Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study.” Diabetes care (2022). PMID: 35699949 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae - [68]
Tamer G, Arik S, Tamer I et al.. “Relative vitamin D insufficiency in Hashimoto's thyroiditis.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21751884 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [69]
Denzer C, Karges B, Näke A et al.. “Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus.” European journal of endocrinology (2013). PMID: 23384709 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [70]
Sahakyan K, Klein BE, Lee KE et al.. “Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20332124 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [71]
Chantzichristos D, Persson A, Eliasson B et al.. “Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies.” European journal of endocrinology (2017). PMID: 29066573 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [72]
Okosieme OE, Wijeyaratne CN, Lazarus JH et al.. “Restricted thyroglobulin antibody epitope specificities in subjects with type 1 diabetes mellitus.” European journal of endocrinology (2009). PMID: 19561043 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors - [73]
Pappa A, Koromantzos P, Seremidi K et al.. “Dental caries and periodontal status in children and adolescents with type 1 diabetes mellitus: an umbrella review.” European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2026). PMID: 42270944 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [74]
Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [75]
Shao MM, Scheideman AF, Zhou AM et al.. “Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987896 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [76]
Di Gialleonardo V, de Vries EF, Di Girolamo M et al.. “Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus.” Endocrine reviews (2012). PMID: 22889646 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [77]
Mackay L, Kilbride L, Adamson KA et al.. “Hormone replacement therapy for women with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23744560 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [78]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2013). PMID: 23543528 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [79]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2006). PMID: 17054193 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [80]
Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [81]
Montero N, Webster AC, Royuela A et al.. “Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.” The Cochrane database of systematic reviews (2014). PMID: 25220222 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [82]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [83]
Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [84]
Gatira DN, Getnet M, Liyew B et al.. “Incidence and predictors of diabetic ketoacidosis among adults with type 1 diabetes in Northwest, Ethiopia, 2023: a retrospective cohort study.” BMC public health (2026). PMID: 41957727 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae - [85]
Halpern B, Nery M, Pereira MAA. “Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29846625 ↗
L4CASE_REPORTCited in: Clinical Presentation - [86]
Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [87]
Dunn A, Lam A, Hidalgo L et al.. “Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398662 ↗
L4OTHERCited in: Clinical Presentation - [88]
Schreiner F, Plamper M, Dueker G et al.. “Infancy-Onset T1DM, Short Stature, and Severe Immunodysregulation in Two Siblings With a Homozygous LRBA Mutation.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26745254 ↗
L4OTHERCited in: Clinical Presentation - [89]
Johnson SR, Carter HE, Leo P et al.. “Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.” Diabetes care (2018). PMID: 30523035 ↗
L2OTHERCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [90]
Tsai EB, Sherry NA, Palmer JP et al.. “The rise and fall of insulin secretion in type 1 diabetes mellitus.” Diabetologia (2006). PMID: 16404554 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [91]
Aparna KV, Darshan M, Kulkarni A et al.. “Emphysematous pyelonephritis in children: Lessons from a case report and systematic review.” Journal of pediatric urology (2026). PMID: 42285016 ↗
L4SR_OBSCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [92]
Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗
L2COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [93]
Li X, Zhang X, Dai X et al.. “Proliferative glomerulonephritis with monoclonal immunoglobulin IgG1-κ deposition in a patient with type 1 diabetes: a case report and literature review.” Frontiers in medicine (2026). PMID: 42375207 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [94]
Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [95]
Liu S, Cao C, Wang X. “Autoimmune polyglandular syndrome type 1 with compound heterozygous AIRE gene pathogenic variants and stage 1 type 1 diabetes mellitus: case report and literature review of Chinese population.” Frontiers in immunology (2026). PMID: 41993177 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment - [96]
Valdivia Camacho OD, Allison T, Wilson LB et al.. “Pediatric Cataracts as a Presenting Sign of Type 1 Diabetes Mellitus.” The Journal of pediatrics (2025). PMID: 40945580 ↗
L4CASE_REPORTCited in: Clinical Presentation - [97]
Maruyama T, Tanaka S, Shimada A et al.. “Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18397986 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [98]
Matejko B, Juza A, Kieć-Wilk B et al.. “Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.” Diabetes care (2022). PMID: 35972259 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [99]
Luijf YM, DeVries JH, Zwinderman K et al.. “Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management.” Diabetes care (2013). PMID: 24170747 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [100]
Ma X, Xie Z, Qin J et al.. “Association of Vitamin D Pathway Gene CYP27B1 and CYP2R1 Polymorphisms with Autoimmune Endocrine Disorders: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32915988 ↗
L3SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [101]
Ludvigsson J, Faresjö M, Hjorth M et al.. “GAD treatment and insulin secretion in recent-onset type 1 diabetes.” The New England journal of medicine (2008). PMID: 18843118 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [102]
Tamborlane WV, Beck RW, Bode BW et al.. “Continuous glucose monitoring and intensive treatment of type 1 diabetes.” The New England journal of medicine (2008). PMID: 18779236 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [103]
Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [104]
Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [105]
Szypowska A, Ramotowska A, Dzygalo K et al.. “Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials.” European journal of endocrinology (2011). PMID: 22096111 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [106]
Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [107]
Orban T, Bundy B, Becker DJ et al.. “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2011). PMID: 21719096 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [108]
Schultz ANØ, Christensen R, Bollig G et al.. “Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.” Diabetologia (2025). PMID: 41198916 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [109]
Benhalima K, van Nes F, Laenen A et al.. “Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.” Diabetologia (2021). PMID: 34647140 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [110]
Gejl M, Gjedde A, Brock B et al.. “Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial.” Diabetologia (2017). PMID: 29188338 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [111]
Golicki DT, Golicka D, Groele L et al.. “Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2007). PMID: 18060380 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [112]
Goldacre RR. “Associations between birthweight, gestational age at birth and subsequent type 1 diabetes in children under 12: a retrospective cohort study in England, 1998-2012.” Diabetologia (2017). PMID: 29128935 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [113]
De Meulemeester J, Keymeulen B, De Block C et al.. “One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.” Diabetologia (2025). PMID: 39934368 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [114]
Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [115]
Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [116]
Prinz N, Tittel SR, Bachran R et al.. “Characteristics of Patients with Type 1 Diabetes and Additional Autoimmune Disease in the DPV Registry.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061946 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [117]
Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [118]
Menon JC, Singh P, Archana A et al.. “High Frequency of Recessive WFS1 Mutations Among Indian Children With Islet Antibody-negative Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37931151 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [119]
Ling P, Yang D, Wang C et al.. “Basal Hyperglycemia Contributes More Than 50% to Time in Range in Pregnant Women With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38686666 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [120]
Demmer RT, Holtfreter B, Desvarieux M et al.. “The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP).” Diabetes care (2012). PMID: 22855731 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [121]
Barrett CE, Park J, Kompaniyets L et al.. “Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.” Diabetes care (2021). PMID: 34158365 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [122]
Epstein EJ, Osman JL, Cohen HW et al.. “Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes.” Diabetes care (2013). PMID: 23596179 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [123]
Scheuing N, Bartus B, Berger G et al.. “Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter german/austrian study.” Diabetes care (2014). PMID: 24623022 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [124]
van Elderen SG, Brandts A, van der Grond J et al.. “Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging.” Diabetes care (2011). PMID: 21216862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [125]
Lundgaard AT, Westergaard D, Röder T et al.. “Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.” Diabetologia (2024). PMID: 39078488 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [126]
Aleksova J, Ebeling PR, Milat F et al.. “DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes.” European journal of endocrinology (2022). PMID: 36315195 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [127]
Martos-Moreno GA, Barrios V, Soriano-Guillén L et al.. “Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy.” European journal of endocrinology (2006). PMID: 17062893 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [128]
Faccinetti NI, Guerra LL, Penas Steinhardt A et al.. “Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants.” European journal of endocrinology (2015). PMID: 26567119 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [129]
Rogowicz-Frontczak A, Zozuliłska-Ziołkiewicz D, Litwinowicz M et al.. “Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?” European journal of endocrinology (2014). PMID: 24480135 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [130]
Krassas GE, Tziomalos K, Pontikides N et al.. “Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population.” European journal of endocrinology (2007). PMID: 17535862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [131]
Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [132]
Murray JA, Husby S. “Celiac Disease.” The New England journal of medicine (2026). PMID: 41950475 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [133]
Langendam M, Luijf YM, Hooft L et al.. “Continuous glucose monitoring systems for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22258980 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [134]
Clar C, Waugh N, Thomas S. “Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17443539 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [135]
Mărgineanu C, Usatiuc LO, Sur ML et al.. “The Bidirectional Relationship Between Type 1 Diabetes Mellitus and Obesity in Pediatric Patients: A Systematic Review.” Children (Basel, Switzerland) (2026). PMID: 42353914 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [136]
Ma IH, Huang WL, Liu YL et al.. “Early Retinal Changes Detected Using Optical Coherence Tomography Angiography in Youth with Type 1 Diabetes Mellitus: A Case-Control Study.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41984745 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [137]
Harada K, Okazaki Y, Ichiba T. “Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application.” The American journal of emergency medicine (2026). PMID: 42119276 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [138]
Jiang Y, Cui Y, Su D et al.. “Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42058780 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [139]
Wherrett DK, Bundy B, Becker DJ et al.. “Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.” Lancet (London, England) (2011). PMID: 21714999 ↗
L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [140]
Shao W, Yang K, Lu D et al.. “Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39986331 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification - [141]
Antonoglou G, Knuuttila M, Niemelä O et al.. “Serum 1,25(OH)D level increases after elimination of periodontal inflammation in T1DM subjects.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23940127 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [142]
Mistry S, Gouripeddi R, Raman V et al.. “Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.” Diabetologia (2022). PMID: 36446887 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [143]
Liu GC, Fang F, Zhou J et al.. “Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.” Diabetologia (2012). PMID: 22653270 ↗
L5OTHERCited in: Severity, Staging and Risk Stratification - [144]
Broe R, Rasmussen ML, Frydkjaer-Olsen U et al.. “Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).” Diabetologia (2014). PMID: 24981770 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [145]
Yılmaz UC, Kızılay DÖ, Kurt ÖK et al.. “Autoantibody screening in children who are first-degree relatives of individuals with type 1 diabetes in a sibling-dominant cohort in Turkey: a multicentre study on prevalence, determinants and post-screening parent-child anxiety.” Diabetologia (2026). PMID: 42350669 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [146]
Idrees H, Memon F, Alam R et al.. “Systematic Review and Meta-Analysis of Insulin Dose and Route of Administration Regimens for Diabetic Ketoacidosis in Children and Adolescents.” Journal of clinical medicine (2025). PMID: 41227190 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [147]
Fullerton B, Siebenhofer A, Jeitler K et al.. “Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27362975 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [148]
Fullerton B, Jeitler K, Seitz M et al.. “Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2014). PMID: 24526393 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [149]
Zhang Q, Saad SH, Zhou H et al.. “Development and validation of an interpretable machine learning model for predicting in-hospital hypoglycemia in adults with type 1 diabetes mellitus: a multicenter retrospective study.” Frontiers in endocrinology (2026). PMID: 42095183 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification - [150]
Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗
L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [151]
Cherney DZ, Reich HN, Scholey JW et al.. “The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.” Diabetologia (2013). PMID: 23893332 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies - [152]
Marzuillo P, Iafusco D, Zanfardino A et al.. “Acute Kidney Injury and Renal Tubular Damage in Children With Type 1 Diabetes Mellitus Onset.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33595665 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [153]
Dugan CW, Maloney SK, Abramoff KJ et al.. “Effects of Simulated High Altitude on Blood Glucose Levels During Exercise in Individuals With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34935935 ↗
L1OTHERCited in: Acute Management and Endocrine Emergencies - [154]
Owens LA, Avalos G, Kirwan B et al.. “ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes.” Diabetes care (2012). PMID: 22826448 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [155]
Goedendorp MM, Tack CJ, Steggink E et al.. “Chronic fatigue in type 1 diabetes: highly prevalent but not explained by hyperglycemia or glucose variability.” Diabetes care (2013). PMID: 23949561 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies - [156]
Tsujimoto T, Yamamoto-Honda R, Kajio H et al.. “Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.” Diabetes care (2013). PMID: 23939540 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [157]
Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [158]
Barchetta I, Alessandri C, Bertoccini L et al.. “Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.” European journal of endocrinology (2015). PMID: 26578639 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [159]
Ishida-Oku M, Iwase M, Sugitani A et al.. “A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor.” Diabetologia (2009). PMID: 19911164 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [160]
Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [161]
Beulens JW, Kruidhof JS, Grobbee DE et al.. “Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study.” Diabetologia (2008). PMID: 18626626 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [162]
Gomes JAF, Vasconcelos AR, Nascimento Júnior JRAD et al.. “Perceived Exertion Is Associated with Cardiovascular Strain but Not Glycemic Response to Gym-Based Exercise in Adults with Type 1 Diabetes: An Exploratory Randomized Crossover Trial.” International journal of environmental research and public health (2026). PMID: 42354343 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [163]
Mitchell S, Patwardhan K, Lucocq J et al.. “Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta-analysis.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41904365 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [164]
Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [165]
Skott E, Cai W, Stiernborg M et al.. “Associations of prenatal exposure to maternal autoimmune disorders with a wide spectrum of psychiatric and neurodevelopmental disorders in offspring-a nationwide cohort study.” Human reproduction open (2026). PMID: 42077501 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [166]
Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [167]
Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [168]
Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A et al.. “Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.” Diabetes care (2019). PMID: 31831473 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [169]
Porcellati F, Lucidi P, Candeloro P et al.. “Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.” Diabetes care (2018). PMID: 30305345 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [170]
Rys PM, Ludwig-Slomczynska AH, Cyganek K et al.. “Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies.” European journal of endocrinology (2018). PMID: 29545258 ↗
L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [171]
Ocheltree SM, Hompesch M, Wondmagegnehu ET et al.. “Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.” European journal of endocrinology (2010). PMID: 20508081 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [172]
Del Favero S, Bruttomesso D, Di Palma F et al.. “First use of model predictive control in outpatient wearable artificial pancreas.” Diabetes care (2014). PMID: 24757228 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [173]
Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [174]
Bergenstal RM, Tamborlane WV, Ahmann A et al.. “Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.” The New England journal of medicine (2010). PMID: 20587585 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [175]
Russell SJ, El-Khatib FH, Sinha M et al.. “Outpatient glycemic control with a bionic pancreas in type 1 diabetes.” The New England journal of medicine (2014). PMID: 24931572 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [176]
Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al.. “Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.” The New England journal of medicine (2009). PMID: 19940299 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [177]
Osipova J, Fischer DC, Dangwal S et al.. “Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24937532 ↗
L4COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [178]
Heller S, Buse J, Fisher M et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521071 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [179]
Beam CA, MacCallum C, Herold KC et al.. “GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.” Diabetologia (2016). PMID: 27704166 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [180]
Thorius IH, Husemoen LLN, Nordsborg RB et al.. “Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.” Diabetologia (2023). PMID: 36640191 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [181]
Al-Naseem AO, Attia A, Gonnah AR et al.. “Pancreas transplantation today: quo vadis?” European journal of endocrinology (2023). PMID: 36929837 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [182]
Wiegand S, Raile K, Reinehr T et al.. “Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy.” European journal of endocrinology (2008). PMID: 18362302 ↗
L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [183]
Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗
L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [184]
Amaral R, Costa B, Penedones A et al.. “Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials.” Diabetes, obesity & metabolism (2026). PMID: 42225295 ↗
L1TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [185]
Bellin MD, Dunn TB. “Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies.” Diabetologia (2020). PMID: 32894315 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [186]
Tamahane V, Shah N, Kajale N et al.. “Effect of prebiotic intervention on glycemic control and gut microbiome profile in Indian children with type 1 diabetes mellitus (T1DM): a pilot randomised control trial.” Endocrine (2026). PMID: 42165942 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [187]
Campbell F, Biggs K, Aldiss SK et al.. “Transition of care for adolescents from paediatric services to adult health services.” The Cochrane database of systematic reviews (2016). PMID: 27128768 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [188]
Abdelghaffar S, Attia AM. “Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.” The Cochrane database of systematic reviews (2009). PMID: 19160294 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [189]
Hemmingsen B, Metzendorf MI, Richter B. “(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2021). PMID: 33662147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [190]
Vardi M, Jacobson E, Nini A et al.. “Intermediate acting versus long acting insulin for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [191]
Misso ML, Egberts KJ, Page M et al.. “Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2010). PMID: 20091571 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [192]
Copur S, Mizrak B, Ozbek L et al.. “Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.” Medeniyet medical journal (2026). PMID: 42383405 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [193]
Toghi-Eshghi SR, Yardley JE. “Morning (Fasting) vs Afternoon Resistance Exercise in Individuals With Type 1 Diabetes: A Randomized Crossover Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31211392 ↗
L1RCTCited in: History and Evolution of Treatment - [194]
Parthasarathy G, Kudva YC, Low PA et al.. “Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27880079 ↗
L1RCTCited in: History and Evolution of Treatment - [195]
Haider DG, Pleiner J, Francesconi M et al.. “Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16895956 ↗
L4RCTCited in: History and Evolution of Treatment - [196]
Sarem Z, Bumke-Vogt C, Mahmoud AM et al.. “Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28911141 ↗
L1RCTCited in: History and Evolution of Treatment - [197]
Crowne EC, Samra JS, Cheetham T et al.. “The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2001). PMID: 11502796 ↗
L1RCTCited in: History and Evolution of Treatment - [198]
Griffen SC, Oostema K, Stanhope KL et al.. “Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16317063 ↗
L1RCTCited in: History and Evolution of Treatment - [199]
Herold KC, Hagopian W, Auger JA et al.. “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037148 ↗
L1RCTCited in: History and Evolution of Treatment - [200]
. “Effects of insulin in relatives of patients with type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037147 ↗
L1RCTCited in: History and Evolution of Treatment - [201]
Nathan DM, Lachin J, Cleary P et al.. “Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.” The New England journal of medicine (2003). PMID: 12788993 ↗
L2RCTCited in: History and Evolution of Treatment - [202]
Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.. “Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.” The New England journal of medicine (2005). PMID: 15972866 ↗
L1RCTCited in: History and Evolution of Treatment - [203]
Skyler JS, Cefalu WT, Kourides IA et al.. “Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.” Lancet (London, England) (2001). PMID: 11210993 ↗
L1RCTCited in: History and Evolution of Treatment - [204]
Shapiro AM, Lakey JR, Ryan EA et al.. “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.” The New England journal of medicine (2000). PMID: 10911004 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [205]
Bally L, Zueger T, Buehler T et al.. “Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study.” Diabetologia (2016). PMID: 26739816 ↗
L1RCTCited in: History and Evolution of Treatment - [206]
Ang M, Meyer C, Brendel MD et al.. “Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.” Diabetologia (2013). PMID: 24305963 ↗
L3RCTCited in: History and Evolution of Treatment - [207]
Garg S, Rosenstock J, Silverman BL et al.. “Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.” Diabetologia (2006). PMID: 16506054 ↗
L1RCTCited in: History and Evolution of Treatment - [208]
Davison GW, Ashton T, George L et al.. “Molecular detection of exercise-induced free radicals following ascorbate prophylaxis in type 1 diabetes mellitus: a randomised controlled trial.” Diabetologia (2008). PMID: 18769906 ↗
L1RCTCited in: History and Evolution of Treatment - [209]
Jenni S, Oetliker C, Allemann S et al.. “Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus--a prospective single-blinded randomised crossover trial.” Diabetologia (2008). PMID: 18512043 ↗
L1RCTCited in: History and Evolution of Treatment - [210]
Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S et al.. “Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.” Lancet (London, England) (2001). PMID: 11418149 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [211]
Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗
L4OTHERCited in: History and Evolution of Treatment - [212]
Galassetti P, Tate D, Neill RA et al.. “Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2002). PMID: 12414885 ↗
L4OTHERCited in: History and Evolution of Treatment - [213]
Kudva YC, Reynolds C, O'Brien T et al.. “"Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes.” Diabetes care (2002). PMID: 11772912 ↗
L3OTHERCited in: History and Evolution of Treatment - [214]
Lu CL, Shen HN, Hu SC et al.. “A Population-Based Study of All-Cause Mortality and Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With Type 1 Diabetes.” Diabetes care (2016). PMID: 27385329 ↗
L3OTHERCited in: History and Evolution of Treatment, Complications and Long-term Sequelae - [215]
Cabrera SM, Chen YG, Hagopian WA et al.. “Blood-based signatures in type 1 diabetes.” Diabetologia (2015). PMID: 26699650 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [216]
Zhang Q, Zhou H, Lin R et al.. “Risk factors for hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis.” BMC endocrine disorders (2025). PMID: 41449374 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [217]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [218]
Tang D, Gao X, Zhu M et al.. “Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.” Clinical pharmacokinetics (2026). PMID: 41489799 ↗
L4RCTCited in: History and Evolution of Treatment - [219]
Drai R, Galstyan G, Karonova T et al.. “Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.” Diabetes, obesity & metabolism (2025). PMID: 41366610 ↗
L1RCTCited in: History and Evolution of Treatment - [220]
Almutairi MNASF. “Neurodevelopmental effects of severe hypoglycemia in children with type 1 diabetes: a systematic review.” Frontiers in pediatrics (2026). PMID: 41660395 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [221]
Aoki TT, Benbarka MM, Okimura MC et al.. “Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.” Lancet (London, England) (1993). PMID: 8102666 ↗
L4OTHERCited in: History and Evolution of Treatment - [222]
Kugathasan L, Katz A, Muskiet MHA et al.. “Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.” Kidney international reports (2026). PMID: 42205183 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [223]
Pham-Dobor G, Kaltenecker P, Temesfoi V et al.. “Systematic Analysis and Network Mapping of Disease Associations in Autoimmune Polyglandular Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39378147 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [224]
Łebkowska A, Adamska A, Krentowska A et al.. “The Influence of Prepubertal Onset of Type 1 Diabetes and Age of Menarche on Polycystic Ovary Syndrome Diagnosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33537700 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [225]
van Dijk M, Donga E, van Dijk JG et al.. “Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus.” Diabetologia (2011). PMID: 21573904 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [226]
Xiao YL, Jia YQ, Gu LQ et al.. “Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.” Journal of digestive diseases (2025). PMID: 41183986 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [227]
Fagerholm E, Ahlqvist E, Forsblom C et al.. “SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.” Diabetologia (2012). PMID: 22643932 ↗
L3SR_OBSCited in: Complications and Long-term Sequelae - [228]
González-Clemente JM, Vilardell C, Broch M et al.. “Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes.” European journal of endocrinology (2007). PMID: 17609399 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [229]
Głowińska-Olszewska B, Moniuszko M, Hryniewicz A et al.. “Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.” European journal of endocrinology (2013). PMID: 23111589 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [230]
Nathan DM. “Realising the long-term promise of insulin therapy: the DCCT/EDIC study.” Diabetologia (2021). PMID: 33550441 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [231]
Chimen M, Kennedy A, Nirantharakumar K et al.. “What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review.” Diabetologia (2011). PMID: 22189486 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [232]
Colombo M, McGurnaghan SJ, Bell S et al.. “Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus.” Diabetologia (2019). PMID: 31807796 ↗
L2OTHERCited in: Complications and Long-term Sequelae - [233]
Cakmak Demir S, Batman A, Yazici D et al.. “Association of High-Risk Obstructive Sleep Apnea with Microvascular Complications in Adults with Type 1 Diabetes Mellitus: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42074704 ↗
L3CASE_CONTROLCited in: Complications and Long-term Sequelae - [234]
Rodrigues F, White M, O'Connell MA. “Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42387672 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [235]
Tentolouris A, Popovic DS, Liarakos AL et al.. “GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.” Diabetes, obesity & metabolism (2026). PMID: 42380553 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [236]
García-Poblet M, Martínez-Sanz JM, Alberola-Chazarra MA et al.. “Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.” Journal of endocrinological investigation (2026). PMID: 42371339 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [237]
Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗
L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [238]
Basu A, Alaupovic P, Wu M et al.. “Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22438226 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [239]
Kim KM, Kim KJ, Han K et al.. “Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37850407 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [240]
Castellaneta S, Piccinno E, Oliva M et al.. “High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.” Diabetes care (2015). PMID: 25784659 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [241]
Allen LA, Cannings-John RL, Evans A et al.. “Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study.” Diabetologia (2019). PMID: 31863141 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [242]
Tosur M, Geyer SM, Rodriguez H et al.. “Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.” Diabetologia (2018). PMID: 29931415 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [243]
García-Patterson A, Gich I, Amini SB et al.. “Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.” Diabetologia (2009). PMID: 20013109 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [244]
Alshehri MS, Alsadoon A, Albazei A et al.. “Pars plana vitrectomy for tractional and combined tractional rhegmatogenous retinal detachment in type 1 diabetes mellitus: outcomes, prognostic factors, and a proposed staging system.” International journal of retina and vitreous (2026). PMID: 42087261 ↗
L2bCited in: Definition, Classification and Axis Nomenclature - [245]
Maciulewski R, Buczyńska-Backiel A, Zielińska-Maciulewska A et al.. “Baseline β-Cell Secretory Reserve and Its Association with Glycaemic Control and Long-Term Outcomes Across Diabetes Phenotypes.” International journal of molecular sciences (2026). PMID: 41752170 ↗
L2bCited in: Definition, Classification and Axis Nomenclature - [246]
İnözü M, Yaşartekin Y, Buluş AD et al.. “Serum uric acid level as a marker associated with microalbuminuria in pediatric patients with type 1 diabetes mellitus.” European journal of pediatrics (2025). PMID: 41329208 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [247]
Abdulla S, Alemadi B, Bin Shafar L et al.. “Prevalence of hypothyroidism among patients undergoing thyroid function tests in primary healthcare centres in Dubai, UAE.” BMC public health (2025). PMID: 40999380 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [248]
Tang N, Su N, Zhang Z et al.. “Retinal vessel metric analysis of type 1 diabetes mellitus in OCT angiography.” Frontiers in medicine (2025). PMID: 40584707 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [249]
Di Giacomo R, Gasparini V, Salvucci G et al.. “Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40571861 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [250]
Bampton TJ, Chen JW, Brown A et al.. “Epidemiology and burden of adult chronic pancreatitis in South Australia: a 20-year data linkage study.” BMJ open (2025). PMID: 40050052 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [251]
Xian J, Du R, Yuan H et al.. “The application of predictive value of diabetes autoantibody profile combined with clinical data and routine laboratory indexes in the classification of diabetes mellitus.” Frontiers in endocrinology (2024). PMID: 39247917 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [252]
Tas N, Mengen E, Alacakır N et al.. “Is there a relationship between hyperchloremia status and the risk of developing acute kidney injury in pediatric patients with diabetic ketoacidosis?” European journal of pediatrics (2024). PMID: 39080001 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [253]
Eken B, Rawshani A, Rawshani A et al.. “Effects of pre-existing type 1 diabetes mellitus on survival outcome following out-of-hospital cardiac arrest: a registry-based observational study in Sweden.” BMJ open (2024). PMID: 39009457 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [254]
Huang X, Ouyang D, Xie W et al.. “Development and validation of machine learning-based diagnostic models using blood transcriptomics for early childhood diabetes prediction.” Frontiers in medicine (2025). PMID: 40740938 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [255]
He X, Wang X, van Heck J et al.. “Blood immune cell profiling in adults with longstanding type 1 diabetes is associated with macrovascular complications.” Frontiers in immunology (2024). PMID: 39011037 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [256]
Casadei G, Baldari M, Brognara L et al.. “Plantar fascia thickness in type 1 diabetes mellitus patients: Clinical associations and metabolic correlates.” Journal of diabetes investigation (2026). PMID: 42046319 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [257]
Gómez-Coronado-Martín R, Salinero-Fort MÁ, López-de-Andrés A et al.. “Clinical Validation of Type 1 Diabetes Coding in Hospital Discharge Records Using ADA Criteria: Implications for Spanish and European Health Data Spaces.” Journal of clinical medicine (2026). PMID: 41899210 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [258]
Bayona Cebada A, Nattero-Chávez L, De la Calle De la Villa E et al.. “Androgen excess disorders remain undiagnosed in one of every four premenopausal women with Type 1 diabetes.” Human reproduction open (2025). PMID: 40747135 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [259]
Yang D, Yang L, Yang J et al.. “Beyond the known: prospective research directions for the gut-brain axis in obesity and type 1 diabetes mellitus.” Diabetology & metabolic syndrome (2026). PMID: 42050719 ↗
L2bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [260]
Chen D, Zhang F, Ren T et al.. “Alterations of sphingosine-1-phosphate and its receptors in type 1 diabetes mellitus: an integrated clinical and single-cell transcriptomic study.” Frontiers in immunology (2026). PMID: 42338584 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [261]
Olson TE, Lloyd TS, Hamad CD et al.. “Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.” JOR spine (2026). PMID: 42253285 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [262]
Min H, Li J, Wang J et al.. “Lipidomic signatures associated with cognitive impairment in type 1 diabetes mellitus: a pilot study integrating clinical serum and mouse hippocampus.” Journal of translational medicine (2026). PMID: 42157048 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [263]
Gómez-Barba JM, Cañete-Massé C, Gallardo-Moreno GB et al.. “Machine learning and regional homogeneity reveal early and subtle brain changes in type 1 diabetes.” Journal of neuroradiology = Journal de neuroradiologie (2026). PMID: 42119663 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [264]
Golodnikov II, Podshivalova ES, Chechekhin VI et al.. “Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes.” JCI insight (2025). PMID: 41325163 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [265]
Mohamed Ali Elbashir R, Elbashir A, Urimuke Basake R et al.. “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.” Cureus (2025). PMID: 41341350 ↗
L1aCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [266]
Marzban M, Ahmadi N, Sotoodehnejadnematalahi F et al.. “Design and application of a multi-epitope ACE2 antigen for detection of autoantibodies in post-COVID-19 diagnosed type 1 diabetes.” Immunology letters (2025). PMID: 41478466 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [267]
Alaei-Shahmiri F, Ghafoury R, Rimaz S et al.. “Attitudes toward Mobile App Use in Individuals with Type 1 Diabetes Mellitus: A Quasi-Experimental Mixed-Methods Investigation of a Digital Support Tool for Diabetes Self-Management Behavior.” Medical journal of the Islamic Republic of Iran (2026). PMID: 42516649 ↗
L2bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [268]
Fantasia KL, Lanzinger S, Rompicherla S et al.. “Missed opportunities for risk reduction: type 1 diabetes management in older adults in DPV and T1DX-QI registries.” Journal of the Endocrine Society (2026). PMID: 41728214 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [269]
Hu Z, Zhu M, Tang L et al.. “Population Pharmacokinetic/Pharmacodynamic Modeling of Volagidemab, a Glucagon Receptor Antagonist, in Healthy Chinese and US Subjects Following Single Subcutaneous Administration.” Pharmaceutical research (2026). PMID: 41714547 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [270]
Xiao W, Zheng D, Guo Q et al.. “Efficacy of Nurse-Led WIKAP Intervention on Hypoglycemia Coping Confidence and Outcomes in Adolescents with Type 1 Diabetes Mellitus: A Quasi-Experimental Study in Zhijiang, China.” Patient preference and adherence (2026). PMID: 42266228 ↗
L1bCited in: Epidemiology, Etiology and Risk Factors - [271]
Alharbi TH, Alzahrani HA, Alromaihi RA et al.. “Immune checkpoint inhibitor-induced type 1 diabetes mellitus: incidence, risk factors, and prognostic implications - a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42456777 ↗
L2aCited in: Epidemiology, Etiology and Risk Factors - [272]
Lu J, Sun S, Shang X et al.. “Association between air pollution exposure and increased chronic kidney disease risk: the modifying effects of genetic susceptibility, transcriptomic, and proteomic signatures.” BMC medicine (2026). PMID: 42106700 ↗
L2bCited in: Epidemiology, Etiology and Risk Factors - [273]
Banerjee M, Maisnam I, Mukhopadhyay P et al.. “Female sexual dysfunction in type 1 diabetes: a systematic review and meta-analysis.” Endocrine (2026). PMID: 42209931 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [274]
Yaman Ortakoylu M, Gonc EN, Ozon A et al.. “Frequency of autoimmune diseases in children and adolescents with type 1 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42445886 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [275]
Astavans A, Baughman D, Mathioudakis N. “Long-Term Major Adverse Cardiovascular and Cerebrovascular Event Risk in Adult-Onset Type 1 Versus Type 2 Diabetes: A Propensity-Matched Cohort Study.” European journal of preventive cardiology (2026). PMID: 42429688 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [276]
Horsdal HT, Heitmann B, Boelt SG et al.. “Neonatal vitamin D levels and autoimmune disorders: a Danish population-based cohort study.” European journal of epidemiology (2026). PMID: 42418142 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [277]
Stalheim AM, Nilsen RM, Vangen S et al.. “Adverse pregnancy outcomes in women with type 1 diabetes: A nationwide, population-based study, 1999-2021.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42169457 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [278]
Robeva R, Kirilov G, Kalinov K et al.. “Autoimmune diseases in patients with different PCOS phenotypes.” Frontiers in reproductive health (2026). PMID: 42099450 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [279]
Yu MH, Hong N, Jeong SH. “Type 1 diabetes and risk of Parkinson's disease: A nationwide nested case-control study.” Parkinsonism & related disorders (2026). PMID: 42214114 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [280]
Yilmaz SK, Ersoy B, Bayar NTI et al.. “Urinary podocalyxin identifies a pre-albuminuric kidney injury window and stratifies 12-year diabetic kidney disease risk in youth with type 1 diabetes mellitus.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 42104992 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [281]
Botella-Juan L, Aguilera-Buenosvinos I, Antequera-González M et al.. “Disordered Eating Behaviours and Associated Factors Among People With Type 1 Diabetes: A Cross-Sectional Study in Spain-D1ANAS Project.” Diabetes/metabolism research and reviews (2026). PMID: 42455961 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [282]
Kongdee R, Parsia B, Thabit H et al.. “Glucose interpretation meaning and action: enhancing type 1 diabetes decision-making with textual descriptions.” Therapeutic advances in endocrinology and metabolism (2025). PMID: 40937073 ↗
L1bCited in: Clinical Presentation - [283]
van Rhijn RI, van Trotsenburg ASP, Mentink R. “Autoantibody-Positive versus Autoantibody-Negative Type 1 Diabetes in Children: Clinical and Biochemical Characteristics.” Hormone research in paediatrics (2026). PMID: 41774599 ↗
L3bCited in: Clinical Presentation - [284]
Muzslay E, Herczeg V, Pusztai RI et al.. “Overweight worsens the metabolic presentation of type 1 diabetes mellitus in children.” Frontiers in endocrinology (2026). PMID: 41585812 ↗
L3bCited in: Clinical Presentation - [285]
Linck JA, Michels C, Schwanstecher A et al.. “Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022-2023.” Diabetes technology & therapeutics (2026). PMID: 41005769 ↗
L4Cited in: Clinical Presentation - [286]
Fu R, Yang M, Guo Y et al.. “Case Report: Case analysis of a juvenile type 1 diabetes mellitus patient with Mauriac syndrome.” Frontiers in endocrinology (2026). PMID: 42528668 ↗
L4Cited in: Clinical Presentation - [287]
Chung JS, Kim JS, Ju JK. “Surgical abdomen masked by metabolic crisis: fulminant ischemic colitis in severe diabetic ketoacidosis - a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42516746 ↗
L5Cited in: Clinical Presentation - [288]
Jin F, Wu W, Yang X et al.. “Dendritic Cells as Immunometabolic Regulatory Nodes in Diabetes: Molecular Mechanisms and Therapeutic Reprogramming.” International journal of molecular sciences (2026). PMID: 42450322 ↗
L5Cited in: Clinical Presentation - [289]
Kouhanjani MF, Plautz A, Melzer N et al.. “Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome.” Autoimmunity reviews (2026). PMID: 42173229 ↗
L5Cited in: Clinical Presentation - [290]
Ilmer S, Sohail R, Hyman S. “25-hydroxyvitamin D and the initial presentation of pediatric type 1 diabetes: associations with ketoacidosis severity and beta-cell function.” Frontiers in endocrinology (2026). PMID: 42169725 ↗
L5Cited in: Clinical Presentation - [291]
Shore B. “Editorial Commentary: Outcomes and Complication Risk in Type 1 Diabetic Patients Undergoing Hip Arthroscopy-Diabetes is NOT a Single Disease.” Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2026). PMID: 41995260 ↗
L5Cited in: Clinical Presentation - [292]
Almallouhi A, Sadek M, Absah I. “Clinical outcome of constipation as the presenting symptom in children with celiac disease.” Journal of pediatric gastroenterology and nutrition (2025). PMID: 41431920 ↗
L5Cited in: Clinical Presentation - [293]
Kahkoska AR, Neumiller JJ, Alexopoulos AS et al.. “Preparing to Meet the Needs of a Growing Older Adult Population with Type 1 Diabetes: A Narrative Review.” Journal of general internal medicine (2025). PMID: 41361045 ↗
L5Cited in: Clinical Presentation - [294]
Fang H, Yin J, Tian S et al.. “Thalamic Nuclei Atrophy in Type 1 Diabetes Mellitus Across Disease Duration.” Journal of magnetic resonance imaging : JMRI (2026). PMID: 42312577 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [295]
Aboelenin HM, ElTaher H, Elzehery R et al.. “Evaluation of FABP1 as a biomarker of diabetic kidney disease in children with type 1 diabetes.” European journal of pediatrics (2026). PMID: 42298045 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [296]
Gülseren A, Koca SB, Seber TU et al.. “The Role of Thyroid Elastography in Children with Type 1 Diabetes Mellitus or Celiac Disease Who Have Negative Thyroid Autoantibodies.” Journal of clinical medicine (2026). PMID: 42074643 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [297]
Styles SE, Haszard JJ, Oravcova-Wheeler Z et al.. “Preliminary Outcomes of a Brief Values-Guided Self-Management Intervention to Improve Glucose Levels Among Emerging Adults With Type 1 Diabetes and Above-Recommended HbA1c: A Pilot Study.” Endocrinology, diabetes & metabolism (2026). PMID: 42234497 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [298]
Mesa Díaz ÁM, Rodríguez de Vera Gómez P, Ruiz Rodríguez M et al.. “Clinical and socioeconomic determinants of glycaemic control derived from continuous glucose monitoring in adults with type 1 diabetes.” Frontiers in endocrinology (2026). PMID: 42109724 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [299]
Boca LO, Ghiga G, Păduraru G et al.. “Pediatric celiac disease and coexisting immune-mediated conditions: a five-year single-center study from North-Eastern Romania.” Frontiers in pediatrics (2026). PMID: 42317660 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [300]
Tang J, Hou Q, Ye J et al.. “Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis.” Frontiers in medicine (2026). PMID: 42524461 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [301]
Hsu JC, Lo FS, Jeng JS et al.. “Association of low-grade albuminuria and triple-line pattern as markers of early peripheral vascular remodeling in adolescents with type 1 diabetes.” Journal of diabetes investigation (2026). PMID: 41804023 ↗
L2bCited in: Severity, Staging and Risk Stratification - [302]
Xiang J, Gao W, Yao Y et al.. “Association between triglyceride-glucose index and diabetic kidney disease in adults with type 1 diabetes.” BMC endocrine disorders (2026). PMID: 41965604 ↗
L3bCited in: Severity, Staging and Risk Stratification - [303]
Bogusz-Górna K, Polańska A, Dańczak-Pazdrowska A et al.. “Selected parameters of epidermal barrier in juveniles with type 1 diabetes correspond with the severity of diabetes - an observational study.” Frontiers in endocrinology (2025). PMID: 41377944 ↗
L3bCited in: Severity, Staging and Risk Stratification - [304]
Capasso G, Guarino S, Tirelli P et al.. “Adrenal response at the onset of type 1 diabetes mellitus in children and its association with acute metabolic and kidney complications.” BMC endocrine disorders (2025). PMID: 41286927 ↗
L3bCited in: Severity, Staging and Risk Stratification - [305]
Abdullah MY, Laaribi AB, Babay W et al.. “Cytokine profiles, genetic polymorphisms, and systemic inflammatory markers in type 1 diabetes patients with COVID-19: IL-18 a predictor of disease severity.” Frontiers in immunology (2026). PMID: 41846929 ↗
L3bCited in: Severity, Staging and Risk Stratification - [306]
Taskin Kursun S, Imre E, Gogas Yavuz D. “Advanced glycation end-products and sclerostin are elevated across diabetes phenotypes and associated with vertebral fractures in type 2 diabetes.” BMC endocrine disorders (2026). PMID: 41963900 ↗
L3bCited in: Severity, Staging and Risk Stratification - [307]
Chakraborty P, Basu M, Mukhopadhyay P et al.. “Study of oral microbiome by next generation sequencing in T1DM adolescents with periodontal disease.” Acta diabetologica (2026). PMID: 41661275 ↗
L3bCited in: Severity, Staging and Risk Stratification - [308]
Haqi Ismael A, Hameed EK. “Insulin resistance in type 1 diabetes: the silent burden unmasked by eGDR.” Acta diabetologica (2026). PMID: 41619053 ↗
L3bCited in: Severity, Staging and Risk Stratification - [309]
Ma D, Xu W, Yang Y et al.. “Efficacy and Safety of Open-Source Hybrid Closed-Loop Automated Insulin Delivery in Perioperative Patients.” Biomedicines (2026). PMID: 42193423 ↗
L1bCited in: Acute Management and Endocrine Emergencies - [310]
Chen H, Lin Z, Liu Z et al.. “Effect of sodium-glucose cotransporter-2 inhibitors on fracture risk in patients with type 1 diabetes receiving insulin-based therapy: a meta-analysis.” PeerJ (2026). PMID: 42011364 ↗
L1aCited in: Acute Management and Endocrine Emergencies - [311]
Ramos Cardona JC, Morecroft R, Martinez S et al.. “Glycemic variability associated with gamma secretase inhibitor therapy in a type 1 diabetic patient undergoing treatment for desmoid tumor: a case report.” Frontiers in endocrinology (2026). PMID: 42147100 ↗
L2bCited in: Acute Management and Endocrine Emergencies - [312]
Montes FR, Gutierrez-Navarro JD, Restrepo-Patiño N et al.. “Perioperative outcomes and phase-specific intraoperative glycemic management in simultaneous pancreas-kidney transplantation: A single-center case series.” World journal of transplantation (2026). PMID: 42281876 ↗
L4Cited in: Acute Management and Endocrine Emergencies - [313]
Girardi KG, Surucu S, Jonnalagadda A et al.. “Type 1 Diabetes Mellitus Correlates With Increased Postoperative Complications and Rates of Conversion to Total Hip Arthroplasty Following Hip Arthroscopy for Femoroacetabular Impingement Syndrome.” Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2026). PMID: 41995211 ↗
L3bCited in: Acute Management and Endocrine Emergencies - [314]
Pellikka I, Ventelä J, Auvinen A et al.. “Association of Childhood Acute Leukemia With Autoimmune Diseases.” International journal of cancer (2026). PMID: 41981796 ↗
L3bCited in: Acute Management and Endocrine Emergencies - [315]
Juhi A, Kumari R, Mondal H et al.. “Objective Sleep and Circadian Metrics in Adolescents With Type 1 Diabetes Mellitus: A Systematic Review.” Journal of diabetes science and technology (2026). PMID: 42449541 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [316]
Yadav J, Kumar J, Kumar R et al.. “Efficacy and safety of stem cell therapy in type 1 diabetes: A systematic review and meta-analysis of randomised controlled trials.” The Indian journal of medical research (2026). PMID: 42397823 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [317]
Reguram R, Shah R, Vora T et al.. “Insulin Pump Use and Hospital Outcomes in Adults With Type 1 Diabetes: A 2022 Nationwide Readmissions Database Analysis.” The Journal of clinical endocrinology and metabolism (2026). PMID: 42530032 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [318]
Cyranka K, Klupa T, Matejko B et al.. “Exploring key targets for psychodiabetological interventions in adults with type 1 diabetes mellitus: an exploratory network and intervention modeling study using Polish MyDiaMate data.” Diabetes research and clinical practice (2026). PMID: 42480716 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [319]
de Lope Quiñones S, Luque-Ramírez M, Quintero Tobar A et al.. “Metabolomic signatures of glycemic control in type 1 diabetes: insights from continuous glucose monitoring.” Journal of endocrinological investigation (2026). PMID: 42474688 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [320]
Shamsnia HS, Peyrovinasab A, Niknejad A et al.. “BCG vaccination as an adjunctive strategy in type 1 diabetes: A systematic review of immunometabolic effects and clinical evidence.” Pathology, research and practice (2026). PMID: 42361719 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [321]
Lü Y, Li Z, Yang Y et al.. “Insulin pump therapy for T1D: a real-world analysis of a novel two-in-one insulin pump in Chinese adults with type 1 diabetes.” Diabetology & metabolic syndrome (2026). PMID: 42332795 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [322]
Gómez AM, Henao-Carrillo D, Muñoz-Velandia O et al.. “Virtual vs. In-Person Training for MinMed™ 780G Initiation: Comparable Effectiveness and Safety in Adults with Type 1 Diabetes.” Clinical medicine insights. Endocrinology and diabetes (2026). PMID: 42482835 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [323]
Cheng Y, Gaborcik JW, Smith RM et al.. “Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis.” The Annals of pharmacotherapy (2026). PMID: 42421396 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [324]
Emilia KK, Magdalena D, Lidia G et al.. “Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41968383 ↗
L1bCited in: History and Evolution of Treatment - [325]
Lee HS, Kim HY, Yang M et al.. “Familial Occurrence of Type 1 Diabetes Mellitus in Korean Children and Adolescents: A Multicenter Study.” Diabetes & metabolism journal (2026). PMID: 41782396 ↗
L3bCited in: History and Evolution of Treatment - [326]
Chen L, Yan C, Huang C et al.. “Upregulation of ADAM19 in dendritic cells is associated with immune features and lower C-peptide levels in type 1 diabetes mellitus.” Diabetology & metabolic syndrome (2026). PMID: 42249412 ↗
L3bCited in: History and Evolution of Treatment - [327]
González-Garrido AA, Gallardo-Moreno GB, Gómez-Barba JM et al.. “Changes in Brain Volumetric Measures Associated With Type 1 Diabetes Depict an Evolutionary Adaptation Process to Developmental Cognitive Demands.” Diabetes/metabolism research and reviews (2026). PMID: 41994900 ↗
L3bCited in: History and Evolution of Treatment - [328]
Rodríguez de Vera Gómez P, Bellido V, Damas Fuentes M et al.. “Development and Validation of Nomogram-Based Predictive Models for Severe Hypoglycemia in Adults With Type 1 Diabetes Treated With Multiple Daily Injections: The SEHYPAN Study.” Diabetes/metabolism research and reviews (2026). PMID: 41791767 ↗
L3bCited in: History and Evolution of Treatment - [329]
Zhu Y, Yang H, Hu C et al.. “Thyroid autoimmunity in relation to islet autoantibodies in newly diagnosed type 1 diabetes mellitus in children and adolescents.” Frontiers in endocrinology (2026). PMID: 42181188 ↗
L3bCited in: History and Evolution of Treatment - [330]
Lipták L, Lipták K, Kempler P et al.. “Early hyperaesthesia and late hypoaesthesia as manifestations of sensory neuropathy in dentistry - two case reports.” Frontiers in endocrinology (2026). PMID: 41685245 ↗
L4Cited in: History and Evolution of Treatment - [331]
Avçin E, Açıkgöz A. “The effect of tele-nursing application on metabolic control, self-efficacy, quality of life and anxiety level in adolescents with Type 1 diabetes: A randomized controlled trial.” Journal of pediatric nursing (2026). PMID: 41653762 ↗
L1bCited in: History and Evolution of Treatment - [332]
Shahim E, Bahrololoom R, Ataollahi M et al.. “Diminished Hepatitis B Antibody Response in Pediatrics With Type 1 Diabetes; the Need for Revaccination Protocol: A Case-Control Study.” Health science reports (2026). PMID: 42528937 ↗
L3bCited in: History and Evolution of Treatment - [333]
Nourbakhsh M, Rouhani F, Razzaghy-Azar M et al.. “Interleukin-6 and Oncostatin M Levels in Patients With Type 1 Diabetes and Its Relationship With Glycemic Indices.” Endocrinology, diabetes & metabolism (2026). PMID: 41917697 ↗
L3bCited in: History and Evolution of Treatment - [334]
Schmolly K, Rudrapatna V, Beaven S. “Recommendations for recognizing and diagnosing Acute Hepatic Porphyria in atypical patient populations.” Orphanet journal of rare diseases (2025). PMID: 41345676 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [335]
Attia N, Al Noaim K, Mustafa M et al.. “The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.” Pediatric diabetes (2025). PMID: 41424588 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [336]
Velardi V, Sanson L, Toffoli B et al.. “Under-recognition of autoimmune polyendocrine syndromes in T1DM: results from an extended screening workup.” Endocrine (2026). PMID: 42541639 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [337]
Adeloye AY, Oyenusi EE, Falokun IB et al.. “Oral manifestations of endocrine disorders among patients attending the paediatric endocrinology clinic in the lagos university teaching hospital: a cross-sectional study.” BMC pediatrics (2026). PMID: 42323555 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [338]
Gamo-Kawasaki M, Kawai S, Takei A et al.. “The clinical significance of SIGLEC1 mRNA levels derived from peripheral leukocytes in autoimmune thyroid diseases and type 1 diabetes.” Endocrine journal (2026). PMID: 42236230 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [339]
Pascual-Morena C, Garrido-Miguel M, Martínez-García I et al.. “Efficacy of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Lipid and Glycemic Profile in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Nutrition reviews (2026). PMID: 42497400 ↗
L1aCited in: Complications and Long-term Sequelae - [340]
Wang Y, Liu J, Cao F et al.. “Association of healthy lifestyle with incident cardiovascular diseases in individuals with type 1 diabetes mellitus: a prospective cohort study.” Diabetology & metabolic syndrome (2026). PMID: 42443959 ↗
L2bCited in: Complications and Long-term Sequelae - [341]
Chu Y, Zhu J, Liu Z et al.. “Metabolic mediators linking type 1 diabetes mellitus to osteoporosis.” Archives of medical science : AMS (2025). PMID: 42110599 ↗
L2bCited in: Complications and Long-term Sequelae - [342]
Chausheva G, Shefket S, Bocheva Y et al.. “Platelet Indices and Adipokines in Adults with Long-Standing Type 1 Diabetes.” Journal of clinical medicine (2026). PMID: 42355786 ↗
L3bCited in: Complications and Long-term Sequelae - [343]
Kietaibl AT, Säemann M, Scherr S et al.. “Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.” Therapeutic advances in endocrinology and metabolism (2026). PMID: 42491266 ↗
L4Cited in: Complications and Long-term Sequelae - [344]
Vayser D, Wang P, Dafesh N et al.. “Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology.” Archives of internal medicine research (2026). PMID: 42306173 ↗
L1bCited in: Complications and Long-term Sequelae - [345]
Zhou X, Yang M, Xue M et al.. “Trends in Diabetes Mellitus Burden and Changes in Attributable Risk Factors in Asia from 1990 to 2021: Results from the Global Burden of Disease Study 2021.” Endocrinology and metabolism (Seoul, Korea) (2026). PMID: 42438067 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [346]
Ozen G, Zanfardino A, Ozen Acan G et al.. “Attenuated Seasonality of Childhood Type 1 Diabetes with Increasing Autoimmune Comorbidities: A 40-year Cohort Study.” Irish journal of medical science (2026). PMID: 42484831 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [347]
Rao S, Li T, Yan Z et al.. “Association between vitamin A and D levels and the risk of type 1 diabetes mellitus in children.” Frontiers in nutrition (2026). PMID: 42358308 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [348]
Li W, Qin L, Gaohui Z et al.. “Incidence and factors associated with hypoglycemia in newly diagnosed hospitalized children and adolescents with type 1 diabetes mellitus in China.” Frontiers in clinical diabetes and healthcare (2026). PMID: 42273407 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [349]
Ramani PK, Haynie CM, Beemarajan E et al.. “GAD65 Antibody-Associated Epilepsy and Autoimmune Encephalitis in Children and Young Adults: A Single-Center Case Series and Review of Literature.” Journal of child neurology (2026). PMID: 42227208 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention